Imidazole derivatives, intermediate, preparation method therefor and use thereof
By synthesizing novel imidazole derivatives, the problems of cyclic stability and side effects of existing α2-adrenergic receptor agonists have been solved, achieving rapid onset of action and high efficacy, making them suitable for the preparation of sedative, analgesic, and other drugs.
Patent Information
- Application Number
- PCT/CN2024/095046
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Existing α2-adrenergic receptor agonists, such as dexmedetomidine, have problems such as poor circulatory stability, large side effects, low potency and slow onset of action during use. In particular, high doses may cause blood pressure fluctuations and decreased heart rate, which makes it difficult to meet clinical needs.
A novel class of imidazole derivatives was developed, which were nucleophilically attacked by acylimidazolium derivatives or formylimidazolium derivatives via lithium-halogen exchange reaction to synthesize intermediates with α2-adrenergic receptor agonist activity. Compounds with good pharmacological effects were prepared by dehydration, hydrogenation reduction and other steps.
This imidazole derivative exhibits good α2-adrenergic receptor agonist activity, has a rapid onset of action, good pharmacokinetic properties and circulatory stability, and few side effects. It is suitable for the preparation of sedative, analgesic, anesthetic, and anti-anxiety drugs and has good prospects for clinical application.
Smart Images

Figure CN2024095046_28112024_PF_FP_ABST
Abstract
Description
Imidazole derivative, intermediate, preparation method and application thereof
[0001] This application claims priority to Chinese application No. 202310592505.0 filed on May 24, 2023, entitled “An Imidazole Derivative, Intermediate, Preparation Method and Application thereof,” the entire contents of which are incorporated herein. Technical Field
[0002] The present invention belongs to the field of medicine, and specifically relates to an imidazole derivative or a pharmaceutically acceptable salt, stereoisomer, tautomer and a composition containing the compound, an intermediate thereof, a preparation method and the application thereof in the field of medicine. Background Art
[0003] Adrenergic receptors are G-protein-coupled receptors, divided into α- and β-adrenergic receptors. Alpha receptors include α1 and α2 receptors, while β receptors include β1, β2, and β3 receptors. α2 receptors are widely distributed in the central and peripheral nervous systems and other organs and tissues (blood vessels, liver, kidneys, pancreas, platelets, etc.). α2A, α2B, and α2C are three subtypes of α2 receptors (Bylund et al., Mol. Pharmacol., 1992, 42, 1-5). α2A in the brain is primarily concentrated in the pons and medulla oblongata, participating in the transmission of sympathetic nerve signals from the central nervous system to the periphery. Stimulation of presynaptic α2A can regulate the release of epinephrine through a negative feedback mechanism; stimulation of postsynaptic α2A can cause hyperpolarization of the nerve cell membrane.
[0004] The effects of α2 receptor agonists on analgesia, anesthesia, and sedation are well documented (Pertovaara, A., Progress in Neurobiology, 40, 691 (1993)). For example, in addition to its well-known sedative effects, systemic administration of clonidine has been shown to produce antinociception in various species, including human patients. Intrathecal and epidural administration of clonidine has also been shown to be effective in producing antinociception. Another α2 receptor agonist, medetomidine, has better α2 / α1 selectivity and is more effective at α2 receptors than clonidine and has been widely used.
[0005] Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that can produce sedation, analgesia, anxiolysis, and sympathetic suppression in the central and peripheral nervous systems and other organs and tissues (Maud AS Weerinks, et al. Clin Pharmacol, 2017, 56:893-913). Due to its significant efficacy, it is currently widely used in clinical practice. While dexmedetomidine has excellent analgesic and sedative effects, its adverse drug reactions should also be taken seriously, particularly hypotension and bradycardia, which are common. Numerous case reports of dexmedetomidine-associated bradycardia progression have been reported. In particular, high doses of dexmedetomidine can stimulate α2B receptors on vascular smooth muscle, causing vasoconstriction and resulting in hypertension and a reflex decrease in heart rate.
[0006] Therefore, it is necessary to find an α2 adrenergic receptor agonist with good circulation stability, high potency, short duration, rapid onset of action in the body and few side effects, and to use it in the preparation of drugs with sedative, and / or analgesic, and / or anesthetic effects, and / or anti-anxiety, and / or sympathetic nerve activity inhibition, and / or treatment of insomnia, and / or treatment of mental disorders.
[0007] Summary of the Invention
[0008] The following is a summary of some aspects of the present invention and is not intended to limit the present invention. In the event of a discrepancy between the disclosure of this specification and a reference, the disclosure of this specification shall prevail.
[0009] The present invention aims to provide an imidazole derivative or pharmaceutically acceptable salt, stereoisomer, tautomer and pharmaceutical composition thereof having α2 adrenergic receptor agonist activity. The compound and pharmaceutical composition can be used to prepare drugs related to α2 adrenergic receptor agonists, and can further be used to prepare drugs that produce sedative, and / or analgesic, and / or anesthetic effects, and / or anti-anxiety, and / or sympathetic nerve activity inhibition, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals. They can further be used to prepare drugs that produce sedative, and / or analgesic, and / or anesthetic effects, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals.
[0010] In one aspect, the present invention provides a compound or a pharmaceutically acceptable salt, stereoisomer, or tautomer represented by the following general formula I:
[0011] Wherein, X is selected from C(R2) p ,O,S,NR2;
[0012] p is selected from 1 and 2;
[0013] n is an integer selected from 1-3, preferably 1;
[0014] Each R1 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl;
[0015] Each R2 is independently selected from H, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, C1-C8 alkylthio, halogen, hydroxy, nitro, cyano, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl, and the substituents are independently selected from halogen, C1-C8 alkoxy, hydroxy, nitro, and cyano;
[0016] R3 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl;
[0017] Ring A is selected from 5-8 membered heterocyclyl, C4-C8 cycloalkyl;
[0018] R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl group optionally substituted by one or more Rb, or a 4-8 membered heterocyclyl group optionally substituted by one or more Rb; the one or more Rb are independently selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; the substituents are independently selected from halogen, C1-C8 alkyl, and hydroxy;
[0019] v is an integer selected from 1-5, preferably an integer from 1-3, more preferably 1 or 2;
[0020] Each R6 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy.
[0021] On the other hand, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by Formula I as described above or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, optionally further comprising a pharmaceutically acceptable excipient, carrier, adjuvant, solvent, or a combination thereof.
[0022] On the other hand, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof, or a pharmaceutical composition thereof for use in preparing drugs related to α2 adrenergic receptor agonists, preferably for use in preparing drugs that produce sedative, and / or analgesic, and / or anesthetic effects, and / or anti-anxiety, and / or sympathetic nerve activity inhibition, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals, and further preferably for use in preparing drugs that produce sedative, and / or analgesic, and / or anesthetic effects, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals.
[0023] In another aspect, the present invention provides a compound as shown in IA, Formula I-A', Formula IB, IC, I-C' or ID, or a salt thereof,
[0024] In Formula IA, n, v, R1, R3, R4, R5, and R6 are as described above;
[0025] R7 is selected from H, C1-C5 alkyl, preferably H, methyl;
[0026] R9 is selected from an amino protecting group; preferably a trityl group;
[0027] In formula I-A', n, v, R1, R3, R4, R5, and R6 are as described above;
[0028] R7 is selected from H, C1-C5 alkyl, preferably H, methyl;
[0029] In Formula IB, X, n, v, R1, R3, R4, R5, and R6 are as described above;
[0030] R9 is selected from an amino protecting group; preferably a trityl group;
[0031] In formula IC, n, v, R1, R3, R4, R5, and R6 are as described above;
[0032] R 10 Selected from C1-C6 alkyl, preferably methyl, ethyl;
[0033] R9 is selected from an amino protecting group; preferably a trityl group;
[0034] In formula I-C', n, v, R1, R3, R4, R5, and R6 are as described above;
[0035] R9 is selected from an amino protecting group; preferably a trityl group;
[0036] In formula ID, n, v, R1, R3, R4, R5, and R6 are as described above;
[0037] R9 is selected from amino protecting groups; preferably trityl.
[0038] In another aspect, the present invention provides a method for preparing an intermediate represented by Formula IC or Formula I-C', comprising the following steps: subjecting a brominated aromatic ring compound to lithium-halogen exchange under the action of butyl lithium, followed by nucleophilic attack on an acyl imidazole derivative to obtain intermediate IC; or subjecting a brominated aromatic ring compound to lithium-halogen exchange under the action of butyl lithium, followed by nucleophilic attack on a formyl imidazole derivative to obtain intermediate I-C';
[0039] n, v, R1, R4, R5, and R6 are as described above;
[0040] R 10 Selected from C1-C6 alkyl, preferably methyl, ethyl;
[0041] R9 is selected from amino protecting groups; preferably trityl. DETAILED DESCRIPTION
[0042] Unless otherwise indicated or there is an obvious conflict in the context, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions provided herein shall prevail. When a trade name appears in this article, it is intended to refer to the corresponding commercial product or its active ingredient. All patents, published patent applications and publications cited herein are incorporated herein by reference.
[0043] General Terms and Definitions
[0044] The term "optional" or "optionally" means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0045] The term "optionally substituted" can be used interchangeably with the term "substituted or unsubstituted", i.e., the structure or group is unsubstituted or substituted with one or more substituents described herein, wherein the substitution occurs at any reasonable position on the given structure or group as allowed by valence. If the substitution occurs on a structure or group that does not allow substitution, the substituent is not present.
[0046] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent. When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such a substituent may be bonded to any ring atom in the substitutable ring.
[0047] In general, the term "substituted" means that one or more hydrogen atoms in a given structure or group are replaced with a specified substituent. Unless otherwise indicated, a substituent may be substituted at every possible position in the group. When more than one position in a given structure can be substituted with one or more of the specified substituents, the substituents may be the same or different at every possible position in the structure.
[0048] In addition, it should be noted that, unless otherwise expressly stated, the description method used in the present invention of "respectively and independently" should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.
[0049] When the lower limit and upper limit of a numerical range are disclosed, any numerical value and any included range falling within the scope are specifically disclosed. In particular, each range of values disclosed herein is understood to represent each numerical value and range encompassed within a wider range. When any variable (such as R), and the variable (such as R1, R2, R3, R4, R5, R6, R7, etc.) with a mark occurs more than once in the composition or structure of a compound, its definition in each case is independent at each occurrence. For example, if a group is substituted with 0, 1, 2 or 3 R substituents, the group can optionally be substituted with three R substituents at most, and the options for each R substituent in each case are independent of each other, i.e., each R substituent can be identical or different.
[0050] Throughout this specification, substituents of the compounds disclosed herein are disclosed in terms of group classes or ranges. It is specifically noted that the present invention includes each independent subcombination of the individual members of these group classes and ranges. For example, the expression mn as used herein refers to the range from m to n, as well as the subranges consisting of the individual values therein, and the individual values.
[0051] The term "alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, which is connected to the rest of the molecule by a single bond. "Alkyl" can have 1 to 8 carbon atoms, i.e., "C1-C8 alkyl", for example, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl, C3 alkyl, C4 alkyl, C8 alkyl, C 1-8 Alkyl, C 3-8 Alkyl groups can have 1-5 carbon atoms, i.e., "C1-C5 alkyl groups"; they can also have 1-3 carbon atoms, i.e., "C1-C3 alkyl groups", for example, C 1-3 Alkyl, C 1-2 Alkyl, C3 alkyl. The term "C1-C5 alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl disclosed independently. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -C(CH3)3), n-pentyl ( -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), n-hexyl (- 2), 2-methyl-3-pentyl (-C(CH3)2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, etc. For example, the expression “C1-C8” or “C 1-8" covers the range of 1-8 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C1-C5, C3-C4, C2-C6, C3-C6, C4-C6, C4-C7, C4-C8, C2-C4, etc., as well as C1, C2, C3, C4, C5, C6, C7, C8, etc. For another example, the expression "C1-C5" or "C 1-5 " covers the range of 1-5 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, etc., as well as C1, C2, C3, C4, C5, etc. For another example, the expression "C2-C5" or "C 2-5 " covers the range of 2-5 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C2-C3, C2-C4, C3-C5, C4-C5, etc., as well as C2, C3, C4, C5, etc. For another example, the expression "C1-C8" or "C 1-8 " covers the range of 1-8 carbon atoms, and should be understood to also cover any subranges therein, as well as each point value, such as C2-C5, C3-C4, C2-C6, C3-C6, C4-C6, C4-C7, C4-C8, C2-C4, etc., as well as C1, C2, C3, C4, C5, C6, C7, C8, etc. For another example, the expression "ternary to octal" should be understood to cover any subranges therein and each point value, such as ternary to pentyl, ternary to hexayl, ternary to heptyl, ternary to octal, quaternary to pentyl, quaternary to hexayl, quaternary to heptyl, quaternary to octal, quinary to quinary, quinary to octal, quinary to octal, quinary to octal, quinary to octal, quinary to octal, quinary to octal, quinary to octal, quinary to octal, etc., as well as 3, 4, 5, 6, 7, 8, etc. Other similar expressions herein should also be understood in a similar manner.
[0052] The term "one or more" or the similar expression "at least one" may mean, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
[0053] The term "selected from..." means one or more elements from the group listed thereafter, selected independently, and may include combinations of two or more elements.
[0054] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.
[0055] When it is stated that each carbon atom in a group may be optionally replaced by a heteroatom, the normal valencies of all atoms in the group in the present circumstances are not exceeded and a stable compound is formed.
[0056] The term "heteroatom" refers to one or more oxygen (O), sulfur (S) or nitrogen (N), including nitrogen (N) and sulfur (S) in any oxidation state; primary, secondary, tertiary amines and quaternary ammonium salts; or a nitrogen atom in a heterocyclic ring in which hydrogen is substituted, for example, N, NH, NR.
[0057] The terms "heterocycle" and "heterocyclyl" are used interchangeably to refer to a monovalent or polyvalent monocyclic, bicyclic, or tricyclic ring system containing 3-14 ring atoms, or 5-8 ring atoms, or 5-6 ring atoms, or 4-8 ring atoms, wherein one or more ring atoms are independently replaced by a heteroatom, wherein the heteroatom has the meaning as described herein, and the ring may be fully saturated or contain one or more degrees of unsaturation. Unless otherwise specified, a -CH2- group in a heterocyclyl group may optionally be replaced by -C(=O)-. The sulfur atom of the ring may optionally be oxidized to form an S-oxide. The nitrogen atom of the ring may optionally be oxidized to form an N-oxide. Examples of heterocyclic groups include 3-14 membered heterocyclic groups, 5-8 membered heterocyclic groups, 5-6 membered heterocyclic groups, 4-8 membered heterocyclic groups, 5-10 membered heterocyclic groups, 5-10 membered monocyclic or bicyclic heterocyclic groups, specifically including: oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl , tetrahydrothiophenyl, dihydrothiophenyl, piperidinyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, morpholinyl, thiomorpholinyl, piperazinyl, cyclopentylpyrimidinyl, dihydrofuropyrimidinyl, dihydropyranopyrimidinyl, dihydropyridinyl, 2-pyridonyl, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, etc. Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-pyridonyl, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidonyl, 3,5-dioxopiperidinyl, and pyrimidinedione. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, sulfolane and 1,1-dioxothiomorpholinyl. The heterocyclic group may be optionally substituted with one or more substituents described herein.
[0058] The term "alkenyl" refers to a general term for hydrocarbons containing a carbon-carbon double bond in the molecule, which is an unsaturated aliphatic hydrocarbon. For example: vinyl (-CH=CH2). The "alkene" can have 2-8 carbon atoms, i.e. "C2-C8" alkenyl, for example C 2-8 Alkenyl, C 2-4 Alkenyl, C 2-5 Alkenyl, C3 alkenyl, C4 alkenyl, C6 alkenyl, C 2- 6 alkenyl, C 3-8 Alkenyl, C3-6 Alkenyl, etc. It can also have 2-4 carbon atoms, i.e. "C2-C4 alkenyl", such as C 2-4 Alkenyl, C 2-3 Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), propenyl (-CH=CH-CH3), butenyl (-CH=CH-CH2-CH3, -CH2-CH=CH-CH3), pentenyl (-CH=CH-CH2-CH2-CH3, -CH2-CH2-CH=CH-CH3, -CH(CH3)-CH=CH-CH3), hexenyl, heptenyl, octenyl, and the like.
[0059] The term "alkyne" is a general term for hydrocarbons containing a carbon-carbon triple bond in the molecule, which is an unsaturated aliphatic hydrocarbon. For example: ethynyl (-C≡CH). The "alkyne" can have 2-8 carbon atoms, i.e. "C2-C8" alkynyl, for example C 2-8 Alkynyl, C 2-4 Alkynyl, C 2-5 Alkynyl, C3 alkynyl, C4 alkynyl, C6 alkynyl, C 2-6 Alkynyl, C 3-8 Alkynyl, C 3-6 Alkynyl, etc. It can also have 2-4 carbon atoms, i.e. "C2-C4 alkynyl", such as C 2- 4-Alkynyl, C 2-3 Alkynyl, C3 alkynyl, C4 alkynyl, etc. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, etc.
[0060] The term "hydrogen (H)" refers to a single hydrogen atom, which may be linked to other groups, such as oxygen atoms, to form a hydroxyl group.
[0061] The term "halogen" or "halo" is understood to mean fluorine (F), chlorine (Cl), bromine (Br) or iodine (I), preferably fluorine, chlorine or bromine atoms, more preferably fluorine or chlorine, and even more preferably a fluorine atom.
[0062] The term "alkoxy" refers to an alkyl group attached to the remainder of the molecule through an oxygen atom, wherein alkyl has the meaning as described herein. In one embodiment, the alkoxy group contains 1-8 carbon atoms. In one embodiment, the alkoxy group contains 1-5 carbon atoms; in another embodiment, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein. Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH3)3), and the like.
[0063] The term "alkylthio" refers to an alkyl group attached to the rest of the molecule through a sulfur atom, wherein the alkyl group is as defined herein. In one embodiment, the alkylthio group contains 1-8 carbon atoms. In one embodiment, the alkylthio group contains 1-5 carbon atoms. In another embodiment, the alkylthio group contains 1-3 carbon atoms. The alkylthio group may be optionally substituted with one or more substituents as described herein. Examples of alkylthio groups include, but are not limited to, methylthio (-SCH3), ethylthio (-SCH2CH3), propylthio (-SCH2CH2CH3, -SCH(CH3)2), butylthio (-SCH2CH2CH2CH3, -SCH2CH(CH3)2, -SCH(CH3)CH2CH3, -SC(CH3)3), and the like.
[0064] The term "cycloalkyl" refers to a cyclic hydrocarbon group or cyclic alkenyl group consisting of carbon atoms and hydrogen atoms, preferably comprising 1 or 2 rings. The cycloalkyl group may be a monocyclic, fused polycyclic, bridged or spirocyclic structure. The cycloalkyl group may have 3 to 8 carbon atoms, i.e., a "C3-C8 cycloalkyl" or a "C3-C8 cycloalkenyl" group, or may have 3 to 6 carbon atoms, i.e., a "C3-C6 cycloalkyl" or a "C3-C6 cycloalkenyl" group, or may have 4 to 8 carbon atoms, i.e., a "C4-C8 cycloalkyl" or a "C4-C8 cycloalkenyl" group, such as a C6 cycloalkyl or cycloalkenyl group, a C5 cycloalkyl or cycloalkenyl group, a C4 cycloalkyl or cycloalkenyl group, or a C3 cycloalkyl or cycloalkenyl group. Examples of cycloalkyl groups include C3-C8 cycloalkyl or cycloalkenyl, C4-C8 cycloalkyl or cycloalkenyl, C4-C6 cycloalkyl or cycloalkenyl, C3-C6 cycloalkyl or cycloalkenyl, specifically including: cyclopropyl, cyclopropenyl, cyclobutenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, etc. The term also encompasses the case where a C atom may be substituted with oxo (=O).
[0065] The terms "hydroxyalkyl" and "hydroxy-substituted alkyl" are used interchangeably and refer to an alkyl group substituted with one or more hydroxy groups. Examples include, but are not limited to, hydroxymethyl (-CH2OH), hydroxyethyl (-CH2CH2OH, -CHOHCH3), hydroxypropyl (-CH2CH2CH2OH, -CH2CHOHCH3, -CHOHCH2CH3, -COHCH3CH3), and hydroxybutyl (-CH2CH2CH2CH2OH, -CH2CH2CHOHCH3, -CHOHCH2CH2CH3, -COHCH3CH2CH3). The above hydroxy substitutions can be mono- or poly-substituted.
[0066] The terms "hydroxyalkoxy" and "hydroxy-substituted alkoxy" are used interchangeably to refer to an alkoxy group substituted with one or more hydroxy groups.
[0067] The terms "haloalkyl" and "halogen-substituted alkyl" are used interchangeably and refer to an alkyl group substituted with one or more halogens. Examples include, but are not limited to, halomethyl, haloethyl, halopropyl, halobutyl, and halopentyl. The halo group may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted. When the methyl group is trihalogen-substituted, trifluoromethyl may be further preferred.
[0068] The terms "haloalkoxy" and "halogen-substituted alkoxy" are used interchangeably and refer to an alkoxy group substituted with one or more halogens. Examples include, but are not limited to, halomethoxy, haloethoxy, halopropoxy, halobutoxy, and halopentoxy, wherein the halo groups may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted.
[0069] The terms "haloalkylthio" and "halogen-substituted alkylthio" are used interchangeably and refer to an alkylthio group substituted with one or more halogens. Examples include, but are not limited to, halomethylthio, haloethylthio, halopropylthio, halobutylthio, and halopentylthio. The halo groups may be monohalogen, dihalogen, or trihalogen.
[0070] The terms "haloalkenyl" and "halogen-substituted alkenyl" are used interchangeably and refer to an alkenyl group substituted with one or more halogens. Examples include, but are not limited to, halovinyl, halopropenyl, halobutenyl, and halopentenyl. The halo groups may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted.
[0071] The terms "haloalkynyl" and "halogen-substituted alkynyl" are used interchangeably and refer to an alkynyl group that is substituted with one or more halogens. Examples include, but are not limited to, haloethynyl, halopropynyl, halobutynyl, and halopentynyl. The halo groups may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted.
[0072] The term "hydroxy" refers to an -OH group.
[0073] Examples of the term "amino protecting group" include, but are not limited to, trityl, benzyloxycarbonyl, tert-butyloxycarbonyl, fluorenylmethoxycarbonyl, allyloxycarbonyl, p-methoxybenzyl, and benzyl.
[0074] “R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl or 4-8 membered heterocyclic group optionally substituted with one or more Rb” means that R4 and R5 can be attached to the same carbon atom in ring A or to different carbon atoms in ring A, that is, R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl or 4-8 membered heterocyclic group optionally substituted with one or more Rb, the latter being fused to ring A to form a fused ring group, or R4, R5 and the carbon atom to which they are attached respectively form a C3-C8 cycloalkyl or 4-8 membered heterocyclic group optionally substituted with one or more Rb, the latter being spiro-fused to ring A to form a spiro ring group. Examples include, but are not limited to: Wherein, m is selected from integers of 0-4, preferably 0, 1, or 2.
[0075] The term "stereoisomers" refers to compounds that have identical chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.
[0076] The term "tautomer" refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization.
[0077] The term "pharmaceutically acceptable salt" refers to an organic salt or an inorganic salt of a compound of the present invention.
[0078] The term "pharmaceutically acceptable carrier" refers to substances that are non-irritating to organisms and do not impair the biological activity and properties of the active compound. "Pharmaceutically acceptable carriers" include, but are not limited to, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavorings, surfactants, wetting agents, dispersants, disintegrants, stabilizers, solvents, or emulsifiers.
[0079] The following detailed description of the invention is intended to illustrate non-limiting embodiments so that other technical personnel in the art can more fully understand the technical solutions, principles and practical applications of the present invention, so that other technical personnel in the art can modify and implement the present invention in many forms to best adapt it to the requirements of specific uses.
[0080] Compounds of formula I
[0081] The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
[0082] Wherein, X is selected from C(R2) p ,O,S,NR2;
[0083] p is selected from 1 and 2;
[0084] n is an integer selected from 1-3, preferably 1;
[0085] Each R1 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl;
[0086] Each R2 is independently selected from H, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, C1-C8 alkylthio, halogen, hydroxy, nitro, cyano, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl, and the substituents are independently selected from halogen, C1-C8 alkoxy, hydroxy, nitro, and cyano;
[0087] R3 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl;
[0088] Ring A is selected from 5-8 membered heterocyclyl, C4-C8 cycloalkyl;
[0089] R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl or 4-8 membered heterocyclyl optionally substituted by one or more Rb; said one or more Rb are independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; said substituents are independently selected from halogen, C1-C8 alkyl, hydroxy;
[0090] v is an integer selected from 1-5, preferably an integer from 1-3, more preferably 1 or 2;
[0091] Each R6 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy.
[0092] In one embodiment, the heterocyclic group is preferably thietanyl, oxetanyl, azetidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, dihydropyrrolyl, dihydropyridinyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl. In a preferred embodiment, the heterocyclic group is selected from thietanyl, oxetanyl, azetidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl. In a particularly preferred embodiment, the heterocyclic group is selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl. In another particularly preferred embodiment, the heterocyclic group is selected from tetrahydrothiophenyl and dihydrothiophenyl.
[0093] In one embodiment, the C1-C8 alkyl group is selected from a C1-C5 alkyl group and a C1-C3 alkyl group. In a specific embodiment, the C1-C8 alkyl group, the C1-C5 alkyl group, and the C1-C3 alkyl group are independently selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a pentyl group, and an isopentyl group. In a more specific embodiment, the C1-C8 alkyl group, the C1-C5 alkyl group, and the C1-C3 alkyl group are independently selected from a methyl group, an ethyl group, a propyl group, and an isopropyl group.
[0094] In one embodiment, the propyl group includes but is not limited to n-propyl (n-Pr, -CH2CH2CH3) or isopropyl (i-Pr, -CH(CH3)2). The butyl group includes but is not limited to n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3) or tert-butyl (t-Bu, -C(CH3)3). The pentyl group includes, but is not limited to, n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2) or 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3).
[0095] In one embodiment, C1-C8 alkoxy is selected from C1-C5 alkoxy and C1-C3 alkoxy. In a specific embodiment, C1-C8 alkoxy, C1-C5 alkoxy and C1-C3 alkoxy are independently selected from methoxy, ethoxy, propoxy, butoxy and pentoxy. In a more specific embodiment, C1-C8 alkoxy, C1-C5 alkoxy and C1-C3 alkoxy are independently selected from methoxy, ethoxy and propoxy.
[0096] In one embodiment, C1-C8 alkylthio is selected from C1-C5 alkylthio and C1-C3 alkylthio. In a specific embodiment, C1-C8 alkylthio, C1-C5 alkylthio and C1-C3 alkylthio are independently selected from methylthio, ethylthio, propylthio, butylthio and pentylthio. In a more specific embodiment, C1-C8 alkylthio, C1-C5 alkylthio and C1-C3 alkylthio are independently selected from methylthio, ethylthio and propylthio.
[0097] In one embodiment, the C1-C8 haloalkyl group is selected from the group consisting of C1-C5 haloalkyl groups. In a preferred embodiment, the C1-C8 haloalkyl group is selected from the group consisting of C1-C3 haloalkyl groups.
[0098] In one embodiment, C1-C8 haloalkoxy is selected from C1-C5 haloalkoxy. In a preferred embodiment, C1-C8 haloalkyl is selected from C1-C3 haloalkoxy.
[0099] In one embodiment, the C1-C8 haloalkylthio group is selected from C1-C5 haloalkylthio groups. In a preferred embodiment, the C1-C8 haloalkyl group is selected from C1-C3 haloalkylthio groups.
[0100] In one embodiment, the C2-C8 alkenyl group is selected from C2-C4 alkenyl groups.
[0101] In one embodiment, the C2-C8 alkynyl group is selected from C2-C4 alkynyl groups.
[0102] In one embodiment, the halo-substituted C2-C8 alkenyl group is selected from halo-substituted C2-C4 alkenyl groups.
[0103] In one embodiment, the halo-substituted C2-C8 alkynyl group is selected from halo-substituted C2-C4 alkynyl groups.
[0104] In one embodiment, the C1-C8 hydroxyalkyl group is selected from C1-C5 hydroxyalkyl groups, preferably C1-C3 hydroxyalkyl groups.
[0105] In one embodiment, the C1-C8 hydroxyalkoxy group is selected from C1-C5 hydroxyalkoxy groups, preferably C1-C3 hydroxyalkoxy groups.
[0106] In one embodiment, the C4-C8 cycloalkyl group is a C4-C6 cycloalkyl group.
[0107] In a preferred embodiment, the C4-C8 cycloalkyl and / or C4-C6 cycloalkyl are selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, cyclohexadienyl, preferably cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, further preferably cyclopentyl and cyclopentenyl.
[0108] In one embodiment, the C3-C8 cycloalkyl group is a C3-C6 cycloalkyl group. In a preferred embodiment, the C3-C8 cycloalkyl group and / or the C3-C6 cycloalkyl group are selected from cyclopropyl, cyclopropenyl, cyclobutenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl, preferably cyclopropyl, cyclopropenyl, cyclobutenyl, and cyclobutyl, and more preferably cyclopropyl and cyclobutyl.
[0109] In one embodiment, the halogen is selected from fluorine, chlorine, bromine, and iodine. In a preferred embodiment, the halogen is selected from fluorine, chlorine, and bromine. In a more preferred embodiment, the halogen is selected from fluorine and chlorine. In a particularly preferred embodiment, the halogen is fluorine.
[0110] In one embodiment, Ring A is selected from a 5-8 membered heterocyclyl containing 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, or a C4-C8 cycloalkyl group, preferably a 5-6 membered heterocyclyl containing 1-2 heteroatoms independently selected from oxygen, sulfur, and nitrogen, or a C4-C6 cycloalkyl group. In one embodiment, the 5-8 membered heterocyclyl and / or 5-6 membered heterocyclyl group is selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, dihydropyrrolyl, dihydropyridinyl, and piperidinyl. In a preferred embodiment, the 5-8 membered heterocyclyl and / or 5-6 membered heterocyclyl group is selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydropyrrolyl, and pyrrolidinyl. In a more preferred embodiment, the 5-8 membered heterocyclyl and / or 5-6 membered heterocyclyl are selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydrothiopyranyl, dihydrothiopyranyl. In a particularly preferred embodiment, the 5-8 membered heterocyclyl and / or 5-6 membered heterocyclyl are selected from tetrahydrothiophenyl and dihydrothiophenyl. In one embodiment, the C4-C8 cycloalkyl and / or C4-C6 cycloalkyl are selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, cyclohexadienyl. In a preferred embodiment, the C4-C8 cycloalkyl and / or C4-C6 cycloalkyl are selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl. In a more preferred embodiment, the C4-C8 cycloalkyl and / or C4-C6 cycloalkyl are selected from cyclopentyl, cyclopentenyl.
[0111] In one embodiment, ring A is selected from 5-6 membered heterocyclic groups containing 1-3 heteroatoms independently selected from oxygen, sulfur and nitrogen, C4-C6 cycloalkyl; preferably 5-6 membered heterocyclic groups containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen, C4-C6 cycloalkyl; further preferably tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, dihydropyrrolyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl, dihydropyridinyl, cyclobutyl, cyclopentyl, cyclohexyl, Cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl; further preferably tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, dihydropyrrolyl, pyrrolidinyl; further selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, cyclopentyl, cyclopentenyl, pyrrolidinyl, tetrahydrothiopyranyl, dihydrothiopyranyl, cyclohexyl, cyclohexenyl.
[0112] In one embodiment, R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl optionally substituted by one or more Rb, or a 4-8 membered heterocyclic radical containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by one or more Rb. In a preferred embodiment, the C3-C8 cycloalkyl is selected from cyclopropyl, cyclopropenyl, cyclobutenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl. In a more preferred embodiment, the C3-C8 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In a particularly preferred embodiment, the C3-C8 cycloalkyl is selected from cyclopropyl, cyclobutyl and cyclopentyl. In another particularly preferred embodiment, the C3-C8 cycloalkyl is selected from cyclopropyl. In a preferred embodiment, the 4-8 membered heterocyclic group containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen is selected from oxetanyl, thietanyl, azetidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, dihydropyrrolyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl and dihydropyridinyl, preferably oxetanyl, thietanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl and dihydrothiophenyl.
[0113] In one embodiment, X is CHR2.
[0114] In one embodiment, R1 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, C1-C8 alkyl, hydroxy, halogen.
[0115] In one embodiment, R2 is selected from H, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, C1-C8 alkylthio, halogen, hydroxy, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, optionally substituted C1-C8 alkyl; the substituents are independently selected from halogen and hydroxy.
[0116] In one embodiment, R3 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl; preferably H, halogen, C1-C8 alkyl;
[0117] In one embodiment, R6 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C8 haloalkylthio, preferably H, halogen, C1-C8 alkyl, further preferably H, C1-C8 alkyl; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy, preferably halogen, further preferably F.
[0118] In one embodiment, Rb is selected from halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, nitro, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C5 haloalkylthio, preferably H, halogen, C1-C5 alkyl, more preferably H, halogen, C1-C3 alkyl; the substituents are independently selected from halogen, C1-C5 alkyl, hydroxy, preferably halogen, more preferably F;
[0119] In one embodiment, R1 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, C1-C5 alkyl, hydroxy, halogen, more preferably H, C1-C3 alkyl, hydroxy, halogen;
[0120] In one embodiment, R2 is selected from H, optionally substituted C1-C5 alkyl, optionally substituted C1-C5 alkoxy, C1-C5 alkylthio, halogen, hydroxy, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, optionally substituted C1-C5 alkyl, further preferably H, optionally substituted C1-C3 alkyl; the substituents are independently selected from halogen, hydroxy;
[0121] In one embodiment, R3 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, halogen, C1-C5 alkyl, more preferably H, halogen, C1-C3 alkyl;
[0122] In one embodiment, R6 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C5 haloalkylthio, preferably H, halogen, C1-C5 alkyl, more preferably H, C1-C3 alkyl; the substituents are independently selected from halogen, C1-C5 alkyl, hydroxy, preferably halogen, more preferably F.
[0123] In one embodiment, R4, R5 and the carbon atoms to which they are respectively attached together form a C3-C8 cycloalkyl group optionally substituted with one or more Rb, which is fused to ring A, preferably any of the following fused ring groups: More preferably More preferably Particularly preferred Wherein, m is selected from integers of 0-4, preferably 0, 1, or 2.
[0124] In one embodiment, R4, R5 and the carbon atoms to which they are respectively attached together form a 4-8 membered heterocyclic group optionally substituted with one or more Rb, which is fused to ring A, preferably forming any of the following fused ring groups: More preferably Wherein, m is selected from integers of 0-4, preferably 0, 1, or 2.
[0125] In one embodiment, R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl group optionally substituted with one or more Rb, which is spiro-bonded to ring A, preferably forming any of the following spirocyclic groups:
[0126] More preferably More preferably Wherein, m is selected from integers of 0-4, preferably 0, 1, or 2.
[0127] In one embodiment, R4, R5 and the carbon atom to which they are attached together form a 4-8 membered heterocyclic group optionally substituted with one or more Rb, which is spiro-bonded to ring A, preferably forming any of the following spirocyclic groups:
[0128] More preferably Wherein, m is selected from integers of 0-4, preferably 0, 1, or 2.
[0129] In one embodiment, Rb is selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, nitro, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C8 haloalkylthio, preferably halogen, C1-C8 alkyl; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy, preferably halogen, and more preferably F.
[0130] In a specific embodiment, Ring A is selected from Preferably More preferably More preferably
[0131] In a specific embodiment, the compound of formula I is represented by formula II:
[0132] wherein Q is selected from C, O, N, and S, preferably C, O, and S;
[0133] y is selected from 1 and 2;
[0134] v is selected from 1, 2, 3 or 4;
[0135] n, X, R1, R3, R4, R5, and R6 are as described above.
[0136] In a specific embodiment, the compound of formula I is represented by formula III:
[0137] wherein v is selected from 1 and 2; and n, X, R1, R3, R4, R5, and R6 are as described above.
[0138] In a specific embodiment, the compound of formula I is represented by formula IV:
[0139] wherein n, v, X, R1, R3, R4, R5, and R6 are as described above.
[0140] In a specific embodiment, the compound of formula I is represented by formula V:
[0141] wherein v is selected from 1 and 2; and n, X, R1, R3, R4, R5, and R6 are as described above.
[0142] In a specific embodiment, the compound of formula I is represented by formula VI:
[0143] Wherein, n, v, X, R1, R3, R4, R5, and R6 are as described above. In a particularly specific embodiment, the compound of formula I is selected from any one of the following compounds:
[0144] Preparation method
[0145] The present invention provides a method for preparing an intermediate represented by formula IC or formula I-C', comprising the following steps: subjecting a brominated aromatic ring compound to lithium-halogen exchange under the action of butyl lithium, followed by nucleophilic attack on an acyl imidazole derivative to obtain intermediate IC; or subjecting a brominated aromatic ring compound to lithium-halogen exchange under the action of butyl lithium, followed by nucleophilic attack on a formyl imidazole derivative to obtain intermediate I-C';
[0146] n, v, R1, R4, R5, and R6 are as described above;
[0147] R 10 Selected from C1-C6 alkyl, preferably methyl, ethyl;
[0148] R9 is selected from amino protecting groups; preferably trityl.
[0149] In some embodiments, intermediate IC is subjected to a dehydration reaction to obtain intermediate IA, which is then subjected to a hydrogenation reduction reaction to obtain intermediate IB, and finally intermediate IB is deprotected by the amino protecting group (eg, trityl) to obtain the compound of formula I.
[0150] In some embodiments, intermediate IC is subjected to simultaneous dehydration and amino protecting group (eg, trityl) to obtain intermediate I-A', and finally intermediate I-A' is hydrogenated and reduced to obtain the compound of formula I.
[0151] In some embodiments, intermediate I-C' is subjected to one-step removal of the amino protecting group (eg, trityl) and simultaneous reduction to obtain the compound of formula I.
[0152] In some embodiments, intermediate I-A' is subjected to a hydroboration-oxidation reaction to obtain a compound of formula I. In some embodiments, intermediate I-C' is subjected to an oxidation reaction to obtain intermediate ID, which is then subjected to an addition reaction to obtain intermediate IC.
[0153] Beneficial technical effects of the present invention
[0154] Compared with the prior art, the technical solution of the present invention has the following advantages:
[0155] The present invention relates to a class of novel structural compounds, which exhibit good α2 adrenergic receptor agonist activity and can be used to prepare drugs related to α2 adrenergic receptor agonists. They can further be used to prepare drugs that produce sedation, and / or analgesia, and / or anesthetic effects, and / or anti-anxiety, and / or inhibition of sympathetic nerve activity, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals. They can further be used to prepare drugs that produce sedation, and / or analgesia, and / or anesthetic effects, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals. These compounds have good pharmacodynamic activity and also exhibit good pharmacokinetic properties, good circulation stability, high potency, short maintenance time, rapid onset of action in the body, and few side effects, and have good clinical application prospects.
[0156] Example
[0157] The following embodiments of the present invention are described in detail. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. Unless otherwise specified, the ratios, percentages, etc. referred to herein are all by weight.
[0158] Synthesis Example
[0159] X, p, n, R1, R2, R3, Ring A, R4, R5, Rb, v, or R6 in Formula (Ia), (Ib), (Ic), (I), (Id), (Ie), (If), (Ig), (Ih), or (Ii) are as defined above.
[0160] Example 1, 2, 4 or 8 Synthesis Flowchart
[0161] The brominated aromatic ring compound undergoes lithium-halide exchange under the action of butyl lithium, and then nucleophilically attacks 1-trityl-4-acetylimidazole to obtain intermediate Ⅰ-a. Ⅰ-a is dehydrated under the action of monoethyl oxalyl chloride / triethylamine to obtain intermediate Ⅰ-b. Ⅰ-b is hydrogenated and reduced under the action of Pd / C to obtain intermediate Ⅰ-c. Ⅰ-c is deprotected under the action of trifluoroacetic acid to obtain the compound shown in formula Ⅰ.
[0162] Example 3 or 9 Synthesis Flowchart
[0163] The brominated aromatic ring undergoes lithium-halide exchange under the action of butyl lithium, and then nucleophilically attacks 1-trityl-4-acetylimidazole to obtain intermediate Ⅰ-a. Under the action of trifluoroacetic acid / triethylsilyl hydride, Ⅰ-a removes the trityl group and water in one step to obtain intermediate Ⅰ-d. Ⅰ-d is hydrogenated and reduced under the action of Pd / C to obtain the compound shown in formula Ⅰ.
[0164] Example 5 or 10 Synthesis Flowchart
[0165] The brominated aromatic ring compound undergoes lithium-halide exchange under the action of butyl lithium, and then nucleophilically attacks 1-trityl-4-formyl imidazole to obtain intermediate Ⅰ-e. Ⅰ-e is further subjected to one-step removal of the trityl group and reduction under the action of trifluoroacetic acid / triethylsilyl hydride to obtain the compound shown in formula Ⅰ.
[0166] Example 6 Synthesis Flowchart
[0167] The brominated aromatic ring undergoes lithium-halide exchange under the action of butyl lithium, and then nucleophilically attacks 1-trityl-4-acetylimidazole to obtain intermediate Ⅰ-a. Under the action of trifluoroacetic acid / triethylsilyl hydride, Ⅰ-a removes the trityl group and water in one step to obtain intermediate Ⅰ-d. Ⅰ-d is hydroborated under the action of borane dimethyl sulfide, and then the reaction is quenched with sodium hydroxide and hydrogen peroxide to obtain the compound shown in formula Ⅰ.
[0168] Example 7 Synthesis Flowchart
[0169] The brominated aromatic ring compound undergoes lithium-halogen exchange under the action of butyl lithium, and then nucleophilically attacks 1-trityl-4-formyl imidazole to obtain intermediate Ⅰ-e. Ⅰ-e is oxidized under the action of manganese dioxide to obtain intermediate Ⅰ-f. Ⅰ-f is added under the action of ethylmagnesium bromide to obtain intermediate Ⅰ-g. Ⅰ-g is dehydrated under the action of monoethyl oxalyl chloride / triethylamine to obtain intermediate Ⅰ-h. Ⅰ-h is hydrogenated and reduced under the action of Pd / C to obtain intermediate Ⅰ-i. Ⅰ-i is deprotected under the action of trifluoroacetic acid to obtain the compound shown in formula Ⅰ.
[0170] Example 1 Preparation of 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-2-yl)ethyl]-1H-imidazole
[0171] 1.1 To a solution of 7-bromo-2,3-dihydroindan-1-one (1.2 g, 5.686 mmol, 1 equiv) in THF (10 mL) and methanol (5 mL) was added portionwise NaBH₄ (1290.5 mg, 34.116 mmol, 6 equiv) at 0°C. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine (3 x 10 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1:1) as the eluent to afford 7-bromo-2,3-dihydro-1H-indan-1-ol (800 mg). (ES, m / z): [M+1] = 214.
[0172] 1.2 To a 40 mL round-bottom flask were added 7-bromo-2,3-dihydro-1H-inden-1-ol (1.1 g, 5.163 mmol, 1 equiv), toluene (10 mL), and TsOH (88.9 mg, 0.516 mmol, 0.1 equiv). The resulting mixture was stirred at 120°C for 2 hours. The resulting mixture was cooled to room temperature and then quenched with water (10 mL) at room temperature. The mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with brine (3 x 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with PE / EA (5:1) to afford 4-bromo-1H-indene (387 mg). (ES, m / z): [M+1] = 196.
[0173] 1.3 To a solution of ZnEt2 (12.82 mL, 12.815 mmol, 5 equiv) in DCM (10 mL) at 0°C under a nitrogen atmosphere was added TFA (1.461 g, 12.815 mmol, 5 equiv) dropwise. The mixture was stirred for 20 minutes, followed by the addition of CH2I2 (3.433 g, 12.815 mmol, 5 equiv) and stirring for 20 minutes. 4-Bromo-1H-indene (500 mg, 2.563 mmol, 1 equiv) was added to the mixture. The resulting mixture was stirred at room temperature overnight. The mixture was quenched with saturated ammonium chloride solution (100 mL). The mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with water (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1:1) as eluent to give 2-bromo-1H,1aH,6H,6aH-cyclopropyl[a]indene (300 mg). (ES, m / z): [M+1]=208,210.
[0174] 1.4 To a solution of 2-bromo-1H,1aH,6H,6aH-cyclopropyl[a]indene (300 mg, 1.435 mmol, 1 equiv) in THF (10 mL) was added dropwise n-butyllithium (0.86 mL, 2.152 mmol, 1.5 equiv, 2.5 M in hexane) at -78°C under a nitrogen atmosphere. Stir for 1 hour, followed by the addition of 1-[1-(triphenylmethyl)imidazol-4-yl]ethanone (606.8 mg, 1.722 mmol). The mixture was warmed to room temperature and stirred overnight. The mixture was quenched with saturated aqueous ammonium chloride (10 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with brine (1 x 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to give 1-[1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl]-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (450 mg). (ES, m / z): [M+1]=483.
[0175] 1.5 To a solution of 1-[1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl]-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (550 mg, 1.140 mmol, 1 equiv) in DCM (10 mL) at room temperature under nitrogen atmosphere was added TEA (691.9 mg, 6.840 mmol, 6 equiv). The mixture was stirred for 2 minutes, cooled to 0°C, and then ethyl oxalyl chloride (466.7 mg, 3.420 equiv, 3 equiv) was added. The resulting mixture was stirred at room temperature overnight and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to give 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl)vinyl]-1-(triphenylmethyl)imidazole (400 mg). (ES, m / z): [M+1] = 465.
[0176] 1.6 To a 20 mL round-bottom flask was added 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl)vinyl]-1-(triphenylmethyl)imidazole (400 mg, 0.861 mmol, 1 equiv), MeOH (8 mL), and Pd / C (109.9 mg, 10% w / t) at room temperature. The resulting mixture was stirred under a hydrogen atmosphere for 1 hour. The resulting mixture was filtered through a pad of Celite, and the filter cake was washed with methanol (1 x 20 mL). The filtrate was concentrated under reduced pressure to afford 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl)ethyl]-1-(triphenylmethyl)imidazole (380 mg, crude). (ES, m / z): [M+1] = 467.
[0177] 1.7 To a 20 mL round-bottom flask was added 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-2-yl)ethyl]-1-(triphenylmethyl)imidazole (380 mg, 0.815 mmol, 1 equiv) and DCM (8 mL) / TFA (2 mL) at room temperature. The resulting mixture was stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography to provide 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-2-yl)ethyl]-1H-imidazole (89.1 mg). (ES, m / z): [M+1] = 225.
[0178] 1 H NMR (400 MHz, methanol-d4) δ 8.67-8.65 (d, J = 7.2 Hz, 1H), 7.34-7.24 (d, J = 43.0 Hz, 1H), 7.06-7.01 (m, 2H), 6.93-6.77 (m, 1H), 4.52-4.46 (m, 1H), 3.17-3.11 (ddd, J = 17.1, 6.8, 2.1 Hz, 1H), 2.9 0-2.86(dd,J=17.3,4.1Hz,1H),2.37–2.27(m,1H),1.82-1.78(dtd,J=10.8,6.7,4.1Hz,1H ),1.71-1.65(dd,J=17.2,7.2Hz,3H),1.06-0.99(tt,J=8.3,4.5Hz,1H),0.11-0.14(m,1H).
[0179] Example 2 Preparation of 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0180] 2.1 To a solution of diethylzinc (76.90 mL, 76.900 mmol, 5 equiv) in DCM (30 mL) at 0°C under a nitrogen atmosphere was added TFA (8.77 g, 76.900 mmol, 5 equiv) dropwise. The mixture was stirred for 20 minutes after addition, followed by the addition of diiodomethane (20.60 g, 76.900 mmol, 5 equiv) at room temperature over 20 minutes. To this mixture was added 4-bromo-3H-indene (3 g, 15.380 mmol, 1 equiv) at room temperature. The mixture was stirred overnight at room temperature. The reaction was quenched with saturated aqueous ammonium chloride (50 mL). The mixture was extracted with ethyl acetate (3 x 20 mL) at room temperature, and the organic layers were combined. The mixture was washed with saturated brine (3 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 5-bromo-1H,1aH,6H,6aH-cyclopropyl[a]indene (1.65 g). (ES, m / z) = 208,210.
[0181] 2.2 To a solution of 5-bromo-1H,1aH,6H,6aH-cyclopropyl[a]indene (1.5 g, 7.174 mmol, 1 equiv) in tetrahydrofuran (20 mL) was added dropwise n-butyllithium (4.30 mL, 10.761 mmol, 1.5 equiv, 2.5 M in hexane) at -78°C under a nitrogen atmosphere. After the addition was complete, the mixture was stirred for 1 hour. Then, a solution of 1-[1-(triphenylmethyl)imidazol-4-yl]ethanone (2.78 g, 7.891 mmol, 1.1 equiv) in THF (5 mL) was added. After the addition was complete, the mixture was slowly warmed to room temperature and stirred overnight. The reaction was quenched with saturated aqueous ammonium chloride (50 mL) at 0°C. The resulting mixture was extracted with EtOAc (3 x 20 mL), and the organic phases were combined, washed with saturated brine (3 x 20 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (1.8 g). (ES, m / z): [M+1] = 483.
[0182] 2.3 To a stirred solution of 1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (1.5 g, 3.108 mmol, 1 equiv) and TEA (1.89 g, 18.648 mmol, 6 equiv) in DCM (20 mL) at 0°C under nitrogen was added ethyl oxalyl chloride (1.27 g, 9.324 mmol, 3 equiv) dropwise. The resulting mixture was stirred at room temperature for 3 hours. The reaction was quenched with water / ice (10 mL) at 0°C and the resulting mixture was extracted with EtOAc (3 x 20 mL). The organic phase was washed with saturated brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5:1) to give 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)vinyl]-1-(triphenylmethyl)imidazole (1.136 g). (ES, m / z): [M+1]=465.
[0183] 2.4 To a stirred solution of 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)vinyl]-1-(triphenylmethyl)imidazole (1.136 g, 2.445 mmol, 1 equiv) in methanol (10 mL) at room temperature was added Pd / C (0.13 g, 10% w / t). The resulting mixture was stirred under a hydrogen atmosphere for 1 hour. The resulting mixture was filtered through a pad of Celite, and the filter cake was washed with methanol (3 x 10 mL). The filtrate was concentrated under reduced pressure. This gave 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)ethyl]-1-(triphenylmethyl)imidazole (1.026 g, crude product). (ES, m / z): [M+1] = 467.
[0184] 2.5 A solution of 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)ethyl]-1-(triphenylmethyl)imidazole (200 mg, 0.4286 mmol, 1 equiv) in DCM (16 mL) and TFA (8 mL) was stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography to give 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole (66.5 mg). (ES, m / z): [M+1] = 225.
[0185] 1H NMR (400 MHz, methanol-d4) δ 8.58 (s, 1H), 7.36–7.18 (m, 2H), 7.11 (td, J = 7.6, 2.3 Hz, 1H), 6.86 (ddd, J = 9.0, 7.7, 1.1 Hz, 1H), 4.43–4.03 (m, 1H), 3.25–2.76 (m, 2H), 2.53–2.27 (m, 1H), 1.92 (tdd, J = 7.7, 5.5, 4.0 Hz, 1H), 1.62 (d, J = 7.2 Hz, 3H), 1.10 (tdd, J = 8.0, 5.6, 4.2 Hz, 1H), 0.00 (ddd, J = 7.4, 4.2, 3.2 Hz, 1H).
[0186] Example 3 Preparation of 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)ethyl]-1H-imidazole
[0187] 3.1 To a stirred solution of 3-bromo-2-hydroxybenzaldehyde (8 g, 39.80 mmol, 1 equiv) and TEA (12.08 g, 119.39 mmol, 3 equiv) in THF (150 mL) at 0°C under a nitrogen atmosphere was added dimethylaminothiocarbonyl chloride (9.84 g, 79.594 mmol, 2 equiv) dropwise. The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The reaction was quenched by the addition of water / ice (100 mL) at 0°C, followed by extraction with EtOAc (3 x 500 mL) and drying over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5:1) to give 1-(2-bromo-6-formylphenoxy)-N,N-dimethylmethanesulfamide (4 g). (ES, m / z): [M+1] = 288, 290.
[0188] 3.2 To a 50 mL two-necked round-bottom flask was added 1-(2-bromo-6-formylphenoxy)-N,N-dimethylmethanesulfamide (3.9 g, 13.534 mmol, 1 equiv) and diphenyl ether (20 mL) at room temperature. The resulting mixture was stirred at 200°C for 30 min under a nitrogen atmosphere. The reaction mixture was cooled to room temperature. The resulting mixture was purified by silica gel column chromatography using PE / EA (4:1) as the eluent to afford 1-(2-bromo-6-formylphenylthio)-N,N-dimethylformamide (3 g) as a yellow solid. (ES, m / z): [M+1] = 288, 290.
[0189] 3.3 To a stirred solution of 1-(2-bromo-6-formylphenylthio)-N,N-dimethylformamide (3 g, 10.41 mmol, 1 equiv) in methanol (25 mL) at room temperature was added a solution of sodium hydroxide (19.99 mL, 1 M). After stirring at 60°C for 2 hours, the reaction mixture was cooled to room temperature, and concentrated hydrochloric acid (15 mL) was added to the mixture. The resulting mixture was stirred at room temperature for an additional 30 minutes. The resulting mixture was extracted with EA (3 x 100 mL), and the organic layers were combined. The mixture was washed with brine (2 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (4:1) as the eluent to give 3-bromo-2-mercaptobenzaldehyde (1.5 g). (ES, m / z): [M-1] = 215, 217.
[0190] 3.4 To a mixture of 3-bromo-2-mercaptobenzaldehyde (1.5 g, 6.91 mmol, 1 equiv) and KCO (1.91 g, 13.82 mmol, 2 equiv) in DMF (20 mL) was stirred at room temperature under nitrogen. The resulting mixture was stirred at 70°C overnight. The reaction mixture was allowed to cool to room temperature and then quenched by addition of water / ice (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 100 mL), and the organic layers were combined. The mixture was washed with brine (3 x 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography to afford 3-bromo-2-[(2-bromoethyl)thio]benzaldehyde (900 mg, 40.20%). (ES,m / z):[M]=321.8,323.8,325.8.
[0191] 3.5 To a 50 mL round-bottom flask was added 3-bromo-2-[(2-bromoethyl)thio]benzaldehyde (700 mg, 2.160 mmol, 1 equiv) and THF (20 mL) at room temperature. Potassium tert-butoxide (363.6 mg, 3.240 mmol, 1.50 equiv) was added portionwise to the above solution at 0°C. The resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography to afford 3-bromo-2-(vinylthio)benzaldehyde (444 mg). (ES, m / z): M = 242, 244.
[0192] 3.6 To a stirred solution of 3-bromo-2-(vinylsulfanyl)benzaldehyde (358 mg, 1.473 mmol, 1 equiv) in CH3OH (20 mL) was added portionwise 4-toluenesulfonylhydrazide (298.9 mg, 1.606 mmol, 1.09 equiv) at room temperature. The resulting mixture was stirred at room temperature overnight. The reaction mixture was filtered, and the filter cake was washed with methanol (3 x 10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography to afford N'-[(1Z)-[3-bromo-2-(vinylsulfanyl)phenyl]methylene]-4-methylbenzenesulfonylhydrazide (600 mg) as a white solid. (ES, m / z): [M+1] = 411, 413.
[0193] 3.7 To a stirred mixture of N'-[(1Z)-[3-bromo-2-(vinylsulfanyl)phenyl]methylene]-4-methylbenzenesulfonylhydrazide (600 mg, 1.459 mmol, 1 equiv) and tert-butoxylithium (124.9 mL, 1.561 mmol, 1.07 equiv) in toluene (10 mL) at room temperature under nitrogen was added rhodium(II) octanoate dimer (22.7 mg, 0.029 mmol, 0.02 equiv). The resulting mixture was stirred at 100°C for 3 hours. The reaction mixture was allowed to cool to room temperature and then quenched by the addition of water (30 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 100 mL), and the organic layers were combined, washed with brine (3 x 100 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. 3-Bromo-1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophene was obtained as a yellow oil. (ES, m / z): M = 226, 228.
[0194] 3.8 A solution of 3-bromo-1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophene (250 mg, 1.10 mmol, 1 equiv) in THF (10 mL) was reacted with n-butyllithium (0.48 mL, 1.211 mmol, 1.1 equiv, 2.5 M in-hexane) at -78°C under nitrogen for 1 hour. 1-[1-(triphenylmethyl)imidazol-4-yl]ethanone (465.5 mg, 1.321 mmol, 1 equiv) was dissolved in THF (2 mL) and added dropwise. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of saturated ammonium chloride (aq). The resulting mixture was extracted with EtOAc (3 × 100 mL), and the organic phases were combined, washed with water (3 × 100 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to give 1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)-1-(1-trityl-1H-imidazol-4-yl)ethan-1-ol (40 mg), (ES, m / z): [M+1]=501.
[0195] 3.9 To a solution of 1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)-1-(1-trityl-1H-imidazol-4-yl)ethan-1-ol (40 mg, 0.080 mmol, 1 equiv) in THF (1 mL) was added TFA (91.10 mg, 0.800 mmol, 10 equiv) at room temperature under a nitrogen atmosphere. After 1 minute, triethylsilane (92.90 mg, 0.800 mmol, 10 equiv) was added dropwise at room temperature. The resulting mixture was reacted at 80°C overnight and then cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography to afford 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)vinyl]-1H-imidazole (18 mg) as a yellow solid. (ES, m / z): [M+1] = 241.
[0196] 3.10 To a solution of 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)vinyl]-1H-imidazole (20 mg, 0.083 mmol, 1 equiv) in MeOH (5 mL) was added Pd / C (10 mg, 10% w / t) at room temperature. The mixture was hydrogenated under a hydrogen blanket for 0.5 h, filtered through a pad of Celite, and concentrated under reduced pressure. Purification by preparative HPLC gave 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)ethyl]-1H-imidazole (1.3 mg). (ES, m / z): [M+1] = 243. 1H NMR (400MHz, methanol-d4) δ7.58–7.51(m,1H),7.19(dt,J=7.6,1.6Hz,1H),6.96(q,J=7.4Hz,1H),6.91–6.76(m,1H),6.76–6.67( m,1H),3.91(q,J=7.1Hz,1H),3.10–2.91(m,2H),1.53(t,J=6.9Hz,3H),0.88(t,J=7.1Hz,1H),0.25(qd,J=4.2,1.6Hz,1H).
[0197] Example 4 Preparation of 4-[1-(2-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0198] The compound was prepared according to the method of Example 1, except that 4-bromo-7-methyl-2,3-dihydro-1H-inden-1-one (commercially available) was used instead of 7-bromo-2,3-dihydroinden-1-one to obtain 4-[1-(2-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole, (ES, m / z): [M+1] = 239.
[0199] 1 H NMR (400 MHz, methanol-d4) δ 8.58 (d, J = 1.4 Hz, 1H), 7.38–7.15 (m, 1H), 7.11–6.84 (m, 1H), 6.72 (dd, J = 10.2, 7.8 Hz, 1H), 4.15 (q, J = 7.2 Hz, 1H), 3.09 (ddd, J = 20.9, 16.8, 6. 7Hz,1H),2.98–2.81(m,1H),2.38(dpd,J=8.0,3.1,1.8Hz,1H),2.33(s,3H),1.89 –1.77(m,1H),1.74–1.51(m,3H),1.10(tt,J=8.2,4.3Hz,1H),0.01–-0.17(m,1H).
[0200] Example 5 Preparation of 4-[(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)methyl]-1H-imidazole
[0201] 5.1 A solution of 5-bromo-1H,1aH,6H,6aH-cyclopropyl[a]indene (300 mg, 1.435 mmol, 1 equiv) in THF (6 mL) was reacted with n-butyllithium (0.86 mL, 2.152 mmol, 1.5 equiv, 2.5 M in-hexane) at -78°C under nitrogen for 1 hour. 1-(Triphenylmethyl)imidazole-4-carbaldehyde (631.2 mg, 1.866 mmol, 1.3 equiv) was then dissolved in THF (2 mL) and added dropwise. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of saturated ammonium chloride (aq). The resulting mixture was extracted with EtOAc (3 x 20 mL), and the organic phases were combined, washed with water (3 x 20 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to give (1,1a,6,6a-tetrahydrocycloprop[a]inden-5-yl)(1-trityl-1H-imidazol-4-yl)methanol (150 mg) as a white solid, (ES, m / z): [M+1]=469.
[0202] 5.2 To a 20 mL round-bottom flask was added (1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)(1-trityl-1H-imidazol-4-yl)methanol (150 mg, 0.320 mmol, 1 equiv) and DCM (6 mL) / TFA (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 3 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography to afford 4-[(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)methyl]-1H-imidazole, (ES, m / z): [M+1] = 211. 1 H NMR (400 MHz, methanol-d4) δ 7.75 (d, J = 1.2 Hz, 1H), 7.21 (d, J = 7.4 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1H), 6.74 (d, J = 1.2 Hz, 1H), 3.89 (s, 2H), 3.10 (dd, J = 17.0, 6.7 Hz,1H),2.94(d,J=17.0Hz,1H),2.43(dddt,J=7.7,6.2,3.1,1.4Hz,1H),1.92(dtd,J =11.4,7.1,6.2,4.2Hz,1H),1.12(tdd,J=8.0,4.1,1.0Hz,1H),0.00(q,J=3.9Hz,1H).
[0203] Example 6 Preparation of 2-(1H, 1aH, 6H, 6aH-cyclopropyl[a]inden-5-yl)-2-(1H-imidazol-4-yl)ethanol
[0204] To a stirred mixture of 4-[1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)vinyl]-1H-imidazole (80 mg, 0.360 mmol, 1 equiv) in THF (5 mL) at 0°C under a nitrogen atmosphere was added BH3-Me2S (2.52 mL, 2.520 mmol, 7 equiv) dropwise. The mixture was stirred at room temperature overnight under a nitrogen atmosphere. To this mixture were added H2O2 (1 mL, 30% w / t) and NaOH (1 mL, 2 M) dropwise at 0°C. The resulting mixture was stirred at room temperature overnight. The reaction was quenched by the addition of water / ice (10 mL) at 0°C and then concentrated under reduced pressure. The crude product (70 mg) was purified by preparative HPLC to give 2-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-2-(1H-imidazol-4-yl)ethanol (6.5 mg). (ES, m / z): [M+1] = 241. 1 H NMR (400MHz, methanol-d4) δ7.56(d,J=1.3Hz,1H),7.12(dd,J=7.4,1.1Hz,1H),7.03(t,J=7.5Hz,1H),6.9 4(dt,J=7.7,1.6Hz,1H),6.77(dt,J=7.0,1.1Hz,1H),4.14(t,J=7.2Hz,1H),4.03(ddd,J=10.9,7.3, 1.8Hz,1H),3.91(ddd,J=10.5,7.1,3.1Hz,1H),3.12(ddd,J=16.9,13.9,6.7Hz,1H),2.96(d,J=16. 9Hz,1H),2.43–2.27(m,1H),1.90–1.79(m,1H),1.03(qd,J=7.7,4.1Hz,1H),-0.07(t,J=3.8Hz,1H).
[0205] Example 7 Preparation of 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)propyl]-1H-imidazole
[0206] 7.1 A solution of 5-bromo-1H,1aH,6H,6aH-cyclopropa[a]indene (350 mg, 1.674 mmol, 1 equiv) in THF (10 mL) was treated with n-butyllithium (1.00 mL, 2.511 mmol, 1.5 equiv, 2.5 M solution in hexane) at -78°C under a nitrogen atmosphere for 1 hour. 1-(Triphenylmethyl)imidazole-4-carbaldehyde (566.5 mg, 1.677 mmol) was then added and allowed to react overnight. The reaction was quenched with saturated ammonium chloride (50 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl[1-(triphenylmethyl)imidazol-4-yl]methanol (600 mg) as a white solid. (ES, m / z): [M+1] = 469.
[0207] 7.2 1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl[1-(triphenylmethyl)imidazol-4-yl]methanol (585 mg, 1.248 mmol, 1 equiv) and manganese dioxide (325.5 mg, 3.744 mmol, 3 equiv) were added to dioxane (10 mL) and stirred at 80°C overnight under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The resulting mixture was filtered and the filter cake was washed with EA (3×10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (6:1) to give 4-(1H,1aH,6H,6aH-cyclopropyl[a]indene-5-carbonyl)-1-(triphenylmethyl)imidazole (420 mg) as a yellow solid. (ES, m / z): [M+1] = 467.
[0208] 7.3 To a stirred solution of 4-(1H,1aH,6H,6aH-cyclopropyl[a]indene-5-carbonyl)-1-(triphenylmethyl)imidazole (433 mg, 0.928 mmol, 1 equiv) in tetrahydrofuran (10 mL) at 0°C under a nitrogen atmosphere was added ethylmagnesium bromide (0.41 mL, 1.392 mmol, 1.5 equiv, 3.4 M in THF) dropwise. The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The reaction was quenched by the addition of saturated ammonium chloride solution. The resulting mixture was extracted with EtOAc (3 x 20 mL), and the combined organic layers were washed with water (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[1-(triphenylmethyl)imidazol-4-yl]propan-1-ol (227 mg) as a pale yellow oil. (ES, m / z): [M+1] = 497.
[0209] 7.4 The compound was prepared according to the method of Example 2, except that 1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[1-(triphenylmethyl)imidazol-4-yl]propan-1-ol (prepared in-house) was used instead of 1-(1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol to give 4-[1-(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)propyl]-1H-imidazole. (ES, m / z): [M+1] = 239. 1 H NMR (400 MHz, methanol-d4) δ 7.57 (t, J = 1.4 Hz, 1H), 7.10 (dd, J = 7.4, 1.2 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.93 (dt, J = 7.6, 1.5 Hz, 1H), 6.74 (s, 1H), 4.00–3.67 (m, 1H), 3.17– 2.76(m,2H),2.35(ddtd,J=7.8,6.0,3.0,1.6Hz,1H),2.17–2.00(m,1H),1.96–1. 77(m,2H),1.09–0.96(m,1H),0.87(td,J=7.4,5.8Hz,3H),-0.08(q,J=3.9Hz,1H).
[0210] Example 8 Preparation of 4-[1-(1a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0211] 8.1 To a stirred solution of 4-bromo-2,3-dihydroindan-1-one (4 g, 18.952 mmol, 1 equiv) in THF (100 mL) at 0°C under a nitrogen atmosphere was added methylmagnesium bromide (7.58 mL, 22.742 mmol, 1.2 equiv, 3 M in THF) dropwise. The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The reaction was quenched by the addition of saturated ammonium chloride (50 mL). The resulting mixture was extracted with EtOAc (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4:1) to give 4-bromo-1-methyl-2,3-dihydroindan-1-ol (3.9 g) as a colorless oil. (ES, m / z): [M] = 226, 228.
[0212] 8.2 To a 20 mL sealed tube was added 4-bromo-1-methyl-2,3-dihydroindan-1-ol (900 mg, 3.963 mmol, 1 equiv), toluene (10 mL), and p-toluenesulfonic acid (88.7 mg, 0.515 mmol, 0.13 equiv) at room temperature. The resulting mixture was stirred at 105°C for 3 hours. The resulting mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (12:1) to give 4-bromo-1-methyl-3H-indene (750 mg) as a colorless oil. (ES, m / z): [M] = 208, 210.
[0213] 8.3 The compound was prepared according to the method of Example 2, but using 4-bromo-1-methyl-3H-indene (homemade) instead of 4-bromo-3H-indene to obtain 4-[1-(1a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole. (ES,m / z):[M+1]=239.15.1H NMR (400MHz, methanol-d4) δ8.43(s,1H),8.06(s,1H),7.14–7.07(m,2H),6.98(s,1H),6.85–6.73(m,1H),4.13(q,J=7.2Hz,1H),3.12–2.98(m,1H) ,2.83(dd,J=28.9,16.9Hz,1H),1.65(dddd,J=8.3,6.4,4.0,2.0Hz,1H),1.55–1.45(m,6H),0.94(dddd,J=8.1,6.8,4.0Hz,1H),0.09(s,1H).
[0214] Example 9 Preparation of 4-[1-(2-hydroxy-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0215] The compound was prepared according to the method of Example 1, except that 4-bromo-7-benzyloxy-2,3-dihydro-1H-inden-1-one (commercially available) was used instead of 7-bromo-2,3-dihydroinden-1-one to give 4-[1-(2-hydroxy-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole, (ES, m / z): [M+1] = 241.00. 1 H NMR (400MHz, methanol-d4) δ7.53 (d, J=6.7Hz, 1H), 6.69 (dd, J=11.3, 8.2Hz, 1H), 6. 64(d,J=5.6Hz,1H),6.51(dd,J=8.2,3.0Hz,1H),3.97(q,J=7.1Hz,1H),3.02 (ddd,J=19.1,12.6,6.8Hz,1H),2.85(dd,J=25.6,16.9Hz,1H),2.41(d,J=8. 2Hz,1H),1.78(s,1H),1.48(dd,J=7.2,1.6Hz,3H),1.08–0.97(m,1H),-0.06 (d,J=4.0Hz,1H).
[0216] Example 10 Preparation of 4-[(1,1a,6,6a-tetrahydrocyclopropyl[a]inden-2-yl)methyl]-1H-imidazole
[0217] The compound was prepared according to the method of Example 5, but 2-bromo-1,1a,6,6a-tetrahydrocyclopropyl[a]indene (homemade) was used instead of 5-bromo-1,1a,6,6a-tetrahydrocyclopropyl[a]indene to obtain 4-[(1,1a,6,6a-tetrahydrocyclopropyl[a]indene-2-yl)methyl]-1H-imidazole, (ES, m / z): [M+1]=211.00.1H NMR(400MHz, methanol-d4)δ7.58(d,J=1.2Hz,1H),7.02–6.93(m,2H),6.90(q,J=4.1Hz ,1H),6.64(q,J=1.1Hz,1H),4.00(s,2H),3.15(dd,J=16.9,6.8Hz,1H),2.89(dt ,J=17.0,1.1Hz,1H),2.35(dddd,J=7.8,6.1,3.3,1.7Hz,1H),1.79(dddd,J=7. 9,6.9,6.1,4.3,0.9Hz,1H),1.03(td,J=7.9,4.1Hz,1H),-0.11(q,J=4.1Hz,1H).
[0218] Example 11 Preparation of 4-[1-(6a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0219] 11.1 To a mixture of 4-bromo-2-methyl-1-indanone (2 g, 8.886 mmol, 1 equiv) in MeOH (15 mL) / THF (30 mL) at 0°C under a nitrogen atmosphere was added NaBH4 (0.67 g, 17.772 mmol, 2 equiv) portionwise and stirred at room temperature for 2 h. The reaction was quenched by the addition of saturated NH4Cl (200 mL), and the resulting mixture was extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with H2O (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (12:1) to afford 4-bromo-2-methyl-1-indanol (1.7 g). (ES, m / z): [M] = 226, 228.
[0220] 11.2 To a mixture of 4-bromo-2-methyl-1-indanol (1.7 g, 7.486 mmol, 1 equiv) in toluene (35 mL) at room temperature under a nitrogen atmosphere was added portionwise TsOH.H₂O (0.14 g, 0.749 mmol, 0.1 equiv). The mixture was heated to 110°C and stirred for 3 h. After the mixture cooled to room temperature, saturated brine (200 mL) was added to quench the reaction. The resulting mixture was extracted with EtOAc (3 x 500 mL), and the combined organic layers were washed with H₂O (3 x 300 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (10:1) as the eluent to afford 4-bromo-2-methyl-3H-indene (1.3 g) as a brown oil. (ES, m / z): [M] = 208, 210.
[0221] 11.3 Under nitrogen at 0°C, TFA (0.89 mL, 11.955 mmol, 5 equiv) was added to a solution of diethylzinc (11.96 mL, 11.955 mmol, 5 equiv) in DCM (45 mL) and stirred for 20 min. Diiodomethane (3.20 g, 11.955 mmol, 5 equiv) was then added dropwise at room temperature. Finally, under nitrogen at room temperature, a solution of 4-bromo-2-methyl-3H-indene (500 mg, 2.391 mmol, 1 equiv) in DCM (2 mL) was added dropwise to the mixture and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (200 mL), and the resulting mixture was extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with H2O (3 x 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (7:1) as eluent to give 5-bromo-6a-methyl-1H,1aH,6H-cyclopropyl[a]indene (300 mg) as a yellow oil. (ES, m / z): [M] = 222, 224.
[0222] 11.4 Under nitrogen at -78°C, n-BuLi (0.64 mL, 1.593 mmol, 1.5 equiv, 2.5 M solution in hexane) was added dropwise to a solution of 5-bromo-6a-methyl-1H,1aH,6H-cyclopropyl[a]indene (237 mg, 1.062 mmol, 1 equiv) in THF (3 mL). After stirring for 1 h, a solution of 1-[1-(trityl)imidazol-4-yl]ethanone (411.81 mg, 1.168 mmol, 1.1 equiv) in THF (1 mL) was slowly added dropwise to the mixture, which was then brought to room temperature and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (50 mL), and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with H2O (3 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. 1-(6a-Methyl-1H,1aH,6H-cyclopropyl[a]inden-5-yl-1-[1-(trityl)imidazol-4-yl]ethanol (400 mg) was obtained as a yellow oil. (ES, m / z): [M+1] = 497.
[0223] 11.5 To a solution of 1-(6a-methyl-1H,1aH,6H-cyclopropyl[a]inden-5-yl-1-[1-(trityl)imidazol-4-yl]ethanol (550 mg, 1.107 mmol, 1 equiv) in DCM (10 mL) at room temperature under nitrogen atmosphere were added triethylsilane (1.29 g, 11.070 mmol, 10 equiv) and TFA (0.82 mL, 11.040 mmol, 9.97 equiv) dropwise, and the mixture was stirred for 1.5 h. The crude product (100 mg) after concentration under reduced pressure was purified by pre-HPLC under the following conditions: Column: XBridge Prep OBD C18 column 30*150 mm, 5 μm; Mobile phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH3.H2O), mobile phase B: MeOH; flow rate: 60 mL / min; gradient: 26% B to 44% B, 10 min; wavelength: 254 nm / 220 m; RT1 (min): 2, to obtain 4-(1-(6a-methyl-1H,1aH,6H-cyclopropyl[a]indene-5-vinyl)-1H-imidazole (190 mg). (ES, m / z): [M+1] = 237.
[0224] 11.6 To a mixture of 4-(1-(6a-methyl-1H,1aH,6H-cyclopropyl[a]indene-5-vinyl)-1H-imidazole (170 mg, 0.719 mmol, 1 equiv) in MeOH (3 mL) was added portionwise 10% Pd / C (15.31 mg) at room temperature under a hydrogen atmosphere. The resulting mixture was filtered through a Celite pad, and the filter cake was washed with MeOH (3×10 mL). The filtrate was concentrated under reduced pressure and purified by reverse phase chromatography under the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH 4 HCO 3 ), gradient from 10% to 50% over 10 min; detector, UV 254 nm. 4-[1-(6a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole (71.2 mg) was obtained. (ES, m / z): [M+1] = 239. 1H NMR (400MHz, methanol-d4) δ8.77(s,1H),7.34(d,J=3.4Hz,1H),7.17–7.00(m,2H),6.78(dd,J=7.7,4.5Hz,1H),4.23(q,J=7.1Hz,1H),3.12 –2.79(m,2H),2.13(dt,J=8.1,3.4Hz,1H),1.60(dd,J=7.2,1.8Hz,3H),1.41(s,3H),1.00(dt,J=8.2,4.2Hz,1H),0.23–0.08(m,1H).
[0225] Example 12 Preparation of 4-[(2',3'-dihydrospiro[cyclopropane-1,1'-indene]-4'-yl)methyl]-1H-imidazole
[0226] 12.1 To a solution of 4-bromoindan-1-one (4 g, 18.952 mmol, 1 equiv) and methyltriphenylphosphonium bromide (13.54 g, 37.904 mmol, 2 equiv) in THF (80 mL) was added dropwise potassium tert-butoxide (37.92 mL, 37.904 mmol, 2.00 equiv, 1 M in THF) under nitrogen at 0°C. The mixture was brought to room temperature and stirred overnight. The reaction was quenched with ice-cold water (50 mL) at 0°C. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (12:1) as eluent to give 4-bromo-1-methylene-2,3-dihydroindane (3.8 g) as a yellow oil. (ES, m / z): [M] = 208, 210.
[0227] 12.2 Under nitrogen at 0°C, TFA (4.09 g, 35.870 mmol, 5 equiv) was added to a solution of diethylzinc (35.87 mL, 35.870 mmol, 5 equiv) in DCM (30 mL) and stirred for 20 min. Diiodomethane (9.61 g, 35.870 mmol, 5 equiv) was then added dropwise at room temperature. Finally, under nitrogen at room temperature, a solution of 4-bromo-1-methylene-2,3-dihydroindane (1.5 g, 7.174 mmol, 1 equiv) in DCM (10 mL) was added dropwise to the mixture and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (50 mL), and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1:1) as eluent to give 4'-bromo-2',3'-dihydrospiro[cyclopropane-1,1'-indene] (1.22 g) as a yellow oil. (ES, m / z): [M] = 222,224
[0228] 12.3 Under a nitrogen atmosphere at -78°C, n-BuLi (1.34 mL, 3.362 mmol, 1.5 equiv of a 2.5 M solution in n-hexane) was added dropwise to a solution of 4'-bromo-2',3'-dihydrospiro[cyclopropane-1,1'-indene] (500 mg, 2.241 mmol, 1 equiv) in THF (10 mL). After stirring for 1 h, a solution of 1-[1-(trityl)imidazol-4-yl]ethanone (789.8 mg, 2.241 mmol, 1 equiv) in THF (10 mL) was added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched with ice-cold water (50 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (10:1) as the eluent to afford 1-(2',3'-dihydrospiro[cyclopropane-1,1'-indene]-4'-yl)-1-[1-(trityl)imidazol-4-yl]ethanol (600 mg) as a yellow oil. (ES, m / z): [M+1] = 483.
[0229] 12.4 To a solution of 2',3'-dihydrospiro[cyclopropane-1,1'-indene]-4'-yl[1-(trityl)imidazol-4-yl]methanol (200 mg, 0.414 mmol, 1 equiv) in DCM (5 mL) was added dropwise triethylsilane (1445.6 mg, 12.420 mmol, 30 equiv) and TFA (1417.5 mg, 12.420 mmol, 30 equiv) at room temperature under a nitrogen atmosphere. The mixture was stirred for 3 h. The mixture was concentrated under reduced pressure and purified by reverse-phase chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (0.1% FA), gradient from 10% to 40% over 10 min; detection, UV 220 nm. 4-[(2',3'-dihydrospiro[cyclopropane-1,1'-indene]-4'-yl)methyl]-1H-imidazole (40.8 mg) was obtained. (ES, m / z): [M+1] = 225. 1 H NMR (400MHz, methanol-d4) δ7.57(s,1H),7.03(t,J=7.5Hz,1H),6.90(d,J=7.5Hz,1H),6.64(s,1H),6.5 3(d,J=7.5Hz,1H),3.87(s,2H),2.92(t,J=7.6Hz,2H),2.09(t,J=7.6Hz,2H),1.02–0.78(m,4H).
[0230] Example 13 Preparation of 4-[(2',3'-dihydrospiro[cyclopropane-1,1'-indene]-7'-yl)methyl]-1H-imidazole
[0231] 13.1 To a solution of 7-bromo-2,3-dihydroindan-1-one (1 g, 4.738 mmol, 1 equiv) and methyltriphenylphosphonium bromide (5.92 g, 16.583 mmol, 3.5 equiv) in THF (5 mL) was added dropwise potassium tert-butoxide (5.21 mL, 1.1 equiv, 1 M in THF) under nitrogen at 0°C. The mixture was brought to room temperature and stirred for 3 h. The reaction was quenched with ice-cold water (20 mL) at 0°C. The resulting mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10:1) to afford 7-bromo-1-methylene-2,3-dihydroindan (657 mg) as a yellow oil. (ES, m / z): [M] = 208, 210.
[0232] 13.2 Under nitrogen at 0°C, TFA (545.34 mg, 4.785 mmol, 5 equiv) was added to a solution of diethylzinc (4.78 mL, 4.785 mmol, 5 equiv) in DCM (10 mL) and stirred for 20 min. Diiodomethane (1280.9 mg, 4.785 mmol, 5 equiv) was then added dropwise at room temperature. Finally, under nitrogen at room temperature, a solution of 7-bromo-1-methylene-2,3-dihydroindane (500 mg, 2.563 mmol, 1 equiv) in DCM (10 mL) was added dropwise to the mixture and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (50 mL), and the resulting mixture was extracted with EtOAc (1 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 7'-bromo-2',3'-dihydrospiro[cyclopropane-1,1'-indene] (170 mg). (ES, m / z): [M] = 222,224.
[0233] 13.3 Under a nitrogen atmosphere at -78°C, n-BuLi (1.21 mL, 3.026 mmol, 1.5 equiv, 2.5 M solution in n-hexane) was added dropwise to a solution of 7'-bromo-2',3'-dihydrospiro[cyclopropane-1,1'-indene] (450 mg, 2.017 mmol, 1 equiv) in THF (10 mL). After stirring for 1 h, a solution of 1-[1-(trityl)imidazol-4-yl]ethanone (682.5 mg, 2.017 mmol, 1 equiv) in THF (10 mL) was added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched with saturated NH4Cl solution (20 mL). The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1:1) as the eluent to obtain 2',3'-dihydrospiro[cyclopropane-1,1'-indene]-7'-yl[1-(trityl)imidazol-4-yl]methanol (450 mg) as a yellow oil. (ES, m / z): [M+1] = 483.
[0234] 13.4 To a solution of 2',3'-dihydrospiro[cyclopropane-1,1'-indene]-7'-yl[1-(trityl)imidazol-4-yl]methanol (160 mg, 0.332 mmol, 1 equiv) in DCM (5 mL) was added triethylsilane (578.2 mg, 4.980 mmol, 15 equiv) and TFA (567.01 mg, 4.980 mmol, 15 equiv) dropwise under nitrogen atmosphere at room temperature, and the mixture was stirred for 3 h. The mixture was concentrated under reduced pressure, and the resulting crude product (160 mg) was purified by pre-HPLC using the following conditions: XBridge Shield RP18 OBD column, 30 x 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH₄HCO₃), mobile phase B: MeOH; flow rate: 60 mL / min; gradient: 26% B to 41% B over 10 min; wavelength: 254 nm / 220 m; RT⁻¹ (min): 10.23 / 12.13, yielding 4-[(2',3'-dihydrospiro[cyclopropane-1,1'-indene]-7'-yl)methyl]-1H-imidazole (15.3 mg). (ES, m / z): [M+1] = 225. 1 H NMR (400MHz, methanol-d4) δ7.56(d,J=1.3Hz,1H),7.10–6.92(m,2H),6.88–6.74(m,1H),6.40(d,J=1.3Hz,1H), 3.67(s,2H),2.91(t,J=7.5Hz,2H),1.97(t,J=7.5Hz,2H),1.21(p,J=4.5,4.0Hz,2H),0.83–0.72(m,2H).
[0235] Example 14 Preparation of 4-[(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thien-3-yl)methyl]-1H-imidazole
[0236] 14.1 Under nitrogen at -78°C, n-BuLi (0.29 mL, 0.726 mmol, 1.1 equiv, 2.5 M solution in n-hexane) was added dropwise to a solution of 3-bromo-1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophene (150 mg, 0.660 mmol, 1 equiv) in THF (10 mL). After stirring for 1 h, a solution of 1-[1-(trityl)imidazol-4-yl]ethanone (245.85 mg, 0.726 mmol, 1.1 equiv) in THF (5 mL) was added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched with saturated NH4Cl solution (2 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH4HCO3), gradient from 50% to 70% over 10 min; detector, UV 220 nm. (1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)(1-trityl-1H-imidazol-4-yl)methanol (60 mg) was obtained as a white solid. (ES, m / z): [M+1] = 487.
[0237] 14.2 At room temperature and under nitrogen atmosphere, (1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)(1-trityl-1H-imidazol-4-yl)methanol (60 mg, 0.123 mmol, 1 equiv), THF (1 mL), triethylsilane (143.37 mg, 1.230 mmol, 10 equiv), and TFA (140.59 mg, 1.230 mmol, 10 equiv) were placed in a 6 mL sealed tube. The mixture was stirred at 80°C overnight. After cooling to room temperature, the mixture was concentrated under reduced pressure, and the residue was purified by reverse phase chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH4HCO3), gradient from 0% to 40% over 10 min; detection, UV 220 nm. 4-[(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thien-3-yl)methyl]-1H-imidazole (17.2 mg) was obtained. (ES, m / z): [M+1] = 229. 1H NMR (400MHz, methanol-d4) δ7.90(s,1H),7.02(d,J=7.4Hz,1H),6.77(t,J=7.5Hz,1H),6.74–6.67(m,2H),3.59(s,2H),2 .85(td,J=7.2,4.1Hz,1H),2.73(td,J=8.0,4.3Hz,1H),1.10(ddd,J=12.7,9.5,5.6Hz,1H),0.02(q,J=4.6Hz,1H).
[0238] Example 15 Preparation of 4-[(6a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)methyl]-1H-imidazole
[0239] 15.1 Under nitrogen at -78°C, n-BuLi (0.32 mL, 0.807 mmol, 1.5 equiv, 2.5 M solution in n-hexane) was added dropwise to a solution of 5-bromo-6a-methyl-1H,1aH,6H-cyclopropyl[a]indene (120 mg, 0.538 mmol, 1 equiv) in THF (3 mL). After stirring for 1 h, 1-[1-(trityl)imidazol-4-yl]ethanone (201 mg, 0.594 mmol, 1.10 equiv) was added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched with saturated NH4Cl solution (50 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (3 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. 6a-Methyl-1H,1aH,6H-cyclopropyl[a]inden-5-yl[1-(trityl)imidazol-4-yl]methanol (160 mg) was obtained as a yellow oil.
[0240] 15.2 To a solution of (6a-methyl-1H,1aH,6H-cyclopropyl[a]inden-5-yl[1-(trityl)imidazol-4-yl]methanol (119 mg, 0.247 mmol, 1 equiv) in DCM (2 mL) at room temperature under nitrogen atmosphere were added triethylsilane (286.71 mg, 2.470 mmol, 10 equiv) and TFA (0.18 mL, 2.470 mmol, 10 equiv). The mixture was stirred at room temperature for 1.5 h. The mixture was concentrated under reduced pressure, and the residue (100 mg) was purified by pre-HPLC under the following conditions: Column: XBridge Prep OBD C18 column 30*150 mm, 5 μm; Mobile phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH3.H2O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 26% B to 44% B, 10 min; wavelength: 254 nm / 220 m; RT1 (min): 2, to obtain 4-[(6a-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)methyl]-1H-imidazole (14.8 mg). (ES, m / z): [M+1] = 225. 1 H NMR (400MHz, methanol-d4) δ7.55(d,J=1.3Hz,1H),7.09–6.92(m,2H),6.84(d,J=7.5Hz,1H),6.60(d,J=1.1Hz,1H),3.78(s,2H),2. 99–2.91(m,1H),2.80(d,J=16.9Hz,1H),2.11–2.02(m,1H),1.37(s,3H),0.95(dd,J=7.9,4.0Hz,1H),0.11(t,J=3.6Hz,1H).
[0241] Example 16 Preparation of 4-[1-(1a,2,3,7b-tetrahydro-1H-cyclopropyl[a]naphthalen-4-yl)ethyl]-1H-imidazole
[0242] 16.1 To a mixture of 5-bromo-3,4-dihydro-2H-naphthalen-1-one (1.0 g, 4.443 mmol, 1 equiv) in MeOH (14 mL) / THF (7 mL) at 0°C under a nitrogen atmosphere was added NaBH4 (1.0 g, 26.658 mmol, 6 equiv) portionwise and stirred overnight. The reaction was quenched by the addition of water (20 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 400 mL), and the combined organic layers were washed with H2O (3 x 400 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (3:1) as the eluent to afford 5-bromo-1,2,3,4-tetrahydronaphthalen-1-ol (950 mg) as a colorless oil. (ES, m / z): [M-17] = 209, 211.
[0243] 16.2 To a mixture of 5-bromo-1,2,3,4-tetrahydronaphthalen-1-ol (950.0 mg, 4.183 mmol, 1 equiv) in toluene (2 mL) at room temperature under a nitrogen atmosphere was added TsOH (72.0 mg, 0.418 mmol, 0.1 equiv) portionwise. The mixture was heated to 110°C and stirred for 2 h. After the mixture cooled to room temperature, the resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with H2O (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to afford 1-bromo-7,8-dihydronaphthalene (541 mg) as a yellow oil. (ES, m / z): M = 208, 210.
[0244] 16.3 Under nitrogen at 0°C, TFA (1.5 g, 12.935 mmol, 5 equiv) was added to a solution of diethylzinc (12.9 mL, 12.935 mmol, 5 equiv, 1.0 M in hexanes) in DCM (10 mL) and stirred for 20 min. Diiodomethane (3.5 g, 12.935 mmol, 5 equiv) was then added dropwise at room temperature. Finally, under nitrogen at room temperature, a solution of 1-bromo-7,8-dihydronaphthalene (541.0 mg, 2.587 mmol, 1 equiv) in DCM (10 mL) was added dropwise to the mixture and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (10 mL), and the resulting mixture was extracted with CHCl2 (3 x 100 mL). The combined organic layers were washed with H2O (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE as eluent to give 4-bromo-1H,1aH,2H,3H,7bH-cyclopropyl[a]naphthalene (212 mg) as a colorless oil. (ES, m / z): M = 222, 224.
[0245] 16.4 Under nitrogen at -78°C, n-BuLi (0.5 mL, 1.425 mmol, 1.5 equiv, 2.5 M solution in n-hexane) was added dropwise to a solution of 4-bromo-1H,1aH,2H,3H,7bH-cyclopropyl[a]naphthalene (212.0 mg, 0.950 mmol, 1 equiv) in THF (5 mL). After stirring for 1 h, 1-[1-(trityl)imidazol-4-yl]ethanone (334.88 mg, 0.950 mmol, 1 equiv) was slowly added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl at 0°C. The resulting mixture was extracted with EtOAc (3 x 100 mL), and the combined organic layers were washed with H2O (1 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. 1-{1H,1aa,2H,3H,7bH-cyclopropyl[a]naphthalen-4-yl}-1-[1-(trityl)imidazol-4-yl]ethanol (60 mg) was obtained as a colorless oil. (ES, m / z): [M+1] = 498.
[0246] 16.5 To a solution of 1-(1H,1aa,2H,3H,7bH-cyclopropyl[a]naphthalen-4-yl-1-[1-(trityl)imidazol-4-yl]ethanol (60.0 mg, 0.121 mmol, 1 equiv) in DCM (0.2 mL) was added dropwise triethylsilane (140.4 mg, 1.210 mmol, 10 equiv) and TFA (0.09 mL, 1.210 mmol, 10 equiv) under nitrogen at 40°C and stirred for 2 h. The crude product (100 mg) was concentrated under reduced pressure and purified by reverse phase chromatography under the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH4HCO3), gradient from 10% to 30% over 10 min; detector, UV 254 nm. 4-(1-{1H,1aH,2H,3H,7bH-cyclopropyl[a]naphthalen-4-yl}vinyl)-1H-imidazole (28 mg) was obtained as a white solid. (ES, m / z): [M+1] = 237.
[0247] 16.6 To a mixture of 4-(1-(1H,1aH,2H,3H,7bH-cyclopropyl[a]naphthalen-4-ylvinyl)-1H-imidazole (30.0 mg, 0.127 mmol, 1 equiv) in MeOH (1 mL) was added 10% Pd / C (10 mg) in portions under a hydrogen atmosphere at room temperature. The resulting mixture was filtered, and the filter cake was washed with MeOH (3 x 5 mL). The filtrate was concentrated under reduced pressure and purified by reverse phase chromatography under the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH4HCO3), gradient from 10% to 30% over 10 min; detector, UV 254 nm. 4-[1-(1a,2,3,7b-tetrahydro-1H-cyclopropyl[a]naphthalen-4-yl)ethyl]-1H-imidazolecarboxylate (15.7 mg) was obtained. (ES, m / z): [M+1] = 239. 1 H NMR (400MHz, methanol-d4) δ8.42(d,J=9.0Hz,1H),8.05(d,J=26.7Hz,1H),7.12(dt,J=7.6,2.0Hz,1H),7.05–6.88(m,2H),6.80(ddd,J=8.7,3. 6,1.9Hz,1H),4.45–4.34(m,1H),2.94–2.81(m,1H),2.30–2.08(m,2H),1.98–1.89(m,1H),1.71–1.50(m,5H),0.81(q,J=8.9,7.3Hz,2H).
[0248] Example 17 Preparation of 4-[1-(3-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0249] 17.1 To a mixture of 4-bromo-6-methyl-2,3-dihydroindan-1-one (500.0 mg, 2.221 mmol, 1 equiv) in MeOH (4 mL) / THF (8 mL) at 0°C under a nitrogen atmosphere was added NaBH₄ (504.2 mg, 13.326 mmol, 6 equiv) portionwise and stirred overnight. The reaction was quenched by the addition of water (10 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 200 mL), and the combined organic layers were washed with H₂O (3 x 200 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (3:1) as the eluent to afford 4-bromo-6-methyl-2,3-dihydro-1H-indan-1-ol (504 mg) as a colorless oil. (ES, m / z): [M-17] = 209, 211.
[0250] 17.2 To a mixture of 4-bromo-6-methyl-2,3-dihydro-1H-inden-1-ol (504 mg, 2.219 mmol, 1 equiv) in toluene (10 mL) at room temperature under a nitrogen atmosphere was added TsOH (38.2 mg, 0.222 mmol, 0.1 equiv) portionwise. The mixture was heated to 110°C and stirred for 2 h. After the mixture cooled to room temperature, the resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with H2O (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to afford 4-bromo-6-methyl-3H-indene (176 mg) as a colorless oil. (ES, m / z): M = 208, 210.
[0251] 17.3 Under nitrogen, TFA (479.9 mg, 4.210 mmol, 5 equiv) was added to a solution of diethylzinc (4.2 mL, 4.210 mmol, 5 equiv, 1.0 M in hexanes) in DCM (5 mL) and stirred for 20 min. Diiodomethane (1.1 g, 4.210 mmol, 5 equiv) was then added dropwise at room temperature. Finally, under nitrogen at 0°C, a solution of 4-bromo-6-methyl-3H-indene (176.0 mg, 0.842 mmol, 1 equiv) in DCM (5 mL) was slowly added dropwise over 2 min and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl (10 mL), and the resulting mixture was extracted with CHCl2 (3 x 100 mL). The combined organic layers were washed with H2O (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE as eluent to give 5-bromo-3-methyl-1H,1aH,6H,6aH-cyclopropyl[a]indene (85 mg) as a colorless oil. (ES, m / z): M = 222, 224.
[0252] 17.4 Under nitrogen at -78°C, n-BuLi (36.61 mg, 0.572 mmol, 1.5 equiv) was added dropwise to a solution of 5-bromo-3-methyl-1H,1aH,6H,6aH-cyclopropyl[a]indene (85 mg, 0.381 mmol, 1 equiv) in THF (1 mL). After stirring for 1 h, 1-[1-(trityl)imidazol-4-yl]ethanone (134.27 mg, 0.381 mmol, 1 equiv) was slowly added dropwise to the mixture, which was then stirred at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl at 0°C. The resulting mixture was extracted with EtOAc (3 x 100 mL), and the combined organic layers were washed with H2O (1 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. 1-(3-Methyl-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl-1-[1-(trityl)imidazol-4-yl]ethanol (60 mg) was obtained as a colorless oil. (ES, m / z): [M+1] = 498.
[0253] 17.5 To a solution of 1-(3-methyl-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl-1-[1-(trityl)imidazol-4-yl]ethanol (60 mg, 0.121 mmol, 1 equiv) in DCM (1 mL) at 40° C. under nitrogen atmosphere, triethylsilane (70.24 mg, 0.605 mmol, 5 equiv) and TFA (137.75 mg, 1.210 mmol, 10 equiv) were added dropwise and stirred for 2 h. The crude product was concentrated under reduced pressure and purified by reverse phase chromatography under the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH 4 HCO 3 ), gradient from 10% to 30% over 10 min; detector, UV 254 nm. 4-(1-(3-methyl-1H,1aH,6H,6aH-cyclopropyl[a]indene-5-vinyl)-1H-imidazole (15 mg) was obtained as a colorless oil. (ES, m / z): [M+1] = 237.
[0254] 17.6 To a mixture of 4-(1-(3-methyl-1H,1aH,6H,6aH-cyclopropyl[a]indene-5-vinyl)-1H-imidazole (60 mg, 0.254 mmol, 1 equiv) in MeOH (1 mL) at room temperature under a hydrogen atmosphere was added 10% Pd / C (20 mg) in portions. The resulting mixture was filtered, and the filter cake was washed with MeOH (3 x 10 mL). The filtrate was concentrated under reduced pressure and purified by reverse phase chromatography under the following conditions: column, C18 silica gel; mobile phase, acetonitrile-water (10 mmol / L NH4HCO3), gradient from 10% to 30% over 10 min; detector, UV 254 nm. 4-[1-(3-methyl-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole carboxylate (15.7 mg) was obtained. (ES, m / z): [M+1] = 239. 1 H NMR (400MHz, methanol-d4) δ8.47(s,1H),8.23(s,1H),7.07(d,J=16.0Hz,2H),6.72(s,1H),4.17(q,J=7.2Hz,1H),3.11(dd,J=16.7,6.7Hz,1H),2.87( d,J=16.7Hz,1H),2.42–2.33(m,1H),2.30(s,3H),1.97–1.86(m,1H),1. 61(d,J=7.2Hz,3H),1.10(td,J=7.9,4.1Hz,1H),-0.00(q,J=3.9Hz,1H).
[0255] Example 18 Preparation of 4-[1-(3-fluoro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0256] 18.1 Under nitrogen at room temperature, to a mixture of methanol (10 mL) and THF (20 mL) containing 4-bromo-6-fluoro-2,3-dihydroindan-1-one (2 g, 8.732 mmol, 1 equiv) was added portionwise NaBH4 (1.98 g, 52.392 mmol, 6 equiv). The resulting mixture was stirred at room temperature overnight. The reaction mixture was quenched by addition of saturated brine (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic phases were washed with water (1 x 100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to afford 4-bromo-6-fluoro-2,3-dihydro-1H-indan-1-ol (1.5 g) as a light brown oil. (ES, m / z): [M] = 228, 232.
[0257] 18.2 4-Bromo-6-fluoro-2,3-dihydro-1H-indene-1-ol (1 g, 4.328 mmol, 1 equiv) was added to a solution of p-toluenesulfonic acid (0.07 g, 0.433 mmol, 0.1 equiv) in ACN (5 mL). The resulting mixture was stirred at 70°C overnight under nitrogen. The mixture was then cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (9:1) to give 4-bromo-6-fluoro-3H-indene (400 mg) as a colorless oil. (ES, m / z): [M] = 212, 214.
[0258] 18.3 Under nitrogen at 0°C, a solution of diethylzinc (9.39 mL, 9.390 mmol, 5 equiv) and TFA (1070.39 mg, 9.390 mmol, 5 equiv) was added to DCM (15 mL) and allowed to react for 20 minutes. Diiodomethane (2514.3 mg, 9.390 mmol, 5 equiv) was then added. After 20 minutes, the mixture was added dropwise to a solution of 4-bromo-6-fluoro-3H-indene (400 mg, 1.878 mmol, 1 equiv) in DCM (5 mL). Stirring was continued at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl(aq) (50 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with water (1 x 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to give 5-bromo-3-fluoro-1H,1aH,6H,6aH-cyclopropylimine (273 mg) as a colorless oil. (ES, m / z): [M] = 226,228.
[0259] 18.4 Under nitrogen at -78°C, 5-bromo-3-fluoro-1H,1aH,6H,6aH-cyclopropanylideneindene (264 mg, 1.163 mmol, 1 equiv) was dissolved in THF (5 mL). n-Butyllithium (0.32 mL, 2.018 mmol, 1.5 equiv, 2.5 M in n-hexane) was added and allowed to react for 1 hour. A solution of 1-[1-(trityl)imidazol-4-yl]ethanone (409.75 mg, 1.163 mmol, 1 equiv) in THF (5 mL) was added portionwise. The mixture was brought to room temperature and stirred overnight. The reaction was quenched by the addition of saturated NH4Cl(aq) (50 mL) at 0°C. The resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with brine (1 x 50 mL) and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (5:1) as the eluent to afford 1-{3-fluoro-1H,1aH,6H,6aH-cyclopropylideneinden-5-yl}-1-[1-(trityl)imidazol-4-yl]ethanol (310 mg) as a pale yellow oil. (ES, m / z): [M+1] = 501.
[0260] 18.5 Under nitrogen, 1-{3-fluoro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl}-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (170 mg, 0.340 mmol, 1 equiv) and triethylsilane (1974.3 mg, 17.000 mmol, 50 equiv) were added to DCM and reacted for 1 min. TFA (1936.00 mg, 17.000 mmol, 50 equiv) was then added dropwise at room temperature, and the reaction was stirred for 5 h. The solvent was removed by concentration under reduced pressure. The residue was purified by reverse phase chromatography under the following conditions: C18 silica gel column; mobile phase: water-MeCN (0.1% FA), gradient from 10% to 50% over 10 min; detection: UV 254 nm. 4-(1-{3-fluoro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl}vinyl)-1H-imidazole (50 mg) was obtained as a colorless oil. (ES, m / z): [M+1] = 241.
[0261] 18.6 Under a nitrogen atmosphere, to a solution of 4-(1-{3-fluoro-1H,1aH,6H,6aH-cyclopropyl[a]indol-5-yl}vinyl)-1H-imidazole (50 mg, 0.208 mmol, 1 equiv) in methanol (3 mL) was added Pd / C (11.07 mg, 10%, w / t). The mixture was stirred under hydrogen at room temperature for 25 min. The resulting mixture was filtered through Celite and washed with methanol (3 x 10 mL). The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN-water (0.1% FA), gradient from 10% to 50% over 10 minutes; detection, UV 254 nm. 4-[1-(3-fluoro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole carboxylate (40.7 mg) was obtained. (ES, m / z): [M+1] = 243. 1H NMR (400 MHz, methanol-d4) δ 8.40 (s, 0.5H), 8.12 (s, 1H), 7.14–6.97 (m, 1H), 6.87 (ddd, J = 8.8, 2.4, 1.1 Hz, 1H), 6.55 (ddd, J = 10.5, 8.0, 2.4 Hz, 1H), 4.13 (q, J = 7.1 Hz, 1H), 3.1 2–2.77(m,2H),2.36(tdd,J=6.1,3.0,1.6Hz,1H),1.92(tdd,J=10.5,5.5,3.4Hz,1 H),1.54(dd,J=7.1,2.0Hz,3H),1.08(qd,J=7.7,4.3Hz,1H).0.00(q,J=3.9Hz,1H).
[0262] Example 19 Preparation of 4-[1-(2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)ethyl]-1H-imidazole
[0263] 19.1 Methyltriphenylphosphonium bromide (2012.2 mg, 5.634 mmol, 2 equiv) and potassium tert-butoxide (758.5 mg, 6.761 mmol, 2.4 equiv, 1 M in THF) were added to THF (5 mL) and reacted for one hour at room temperature. 7-bromo-2H-1-benzodifuran-3-one (600 mg, 2.817 mmol, 1 equiv) was then added dropwise at room temperature. The resulting mixture was stirred overnight under nitrogen at room temperature. Upon completion of the reaction, saturated brine (20 mL) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with water (1 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using PE / EA (12:1) as the eluent to afford 7-bromo-3-methylmethylene-2H-1-benzodifuran (298 mg) as a colorless oil. (ES, m / z): [M] = 210, 212.
[0264] 19.2 Under nitrogen at 0°C, diethylzinc solution (6.87 mL, 6.870 mmol, 5 equiv) and TFA (783.3 mg, 6.870 mmol, 5 equiv) were added to DCM (15 mL) and reacted for 20 minutes, followed by the addition of diiodomethane (2514.3 mg, 9.390 mmol, 5 equiv). 7-Bromo-3-methyl-2H-1-benzofuran-3-one (290 mg, 1.374 mmol, 1 equiv) was added to the mixture at room temperature and stirring continued overnight. The reaction was quenched by the addition of saturated NH4Cl solution (20 mL) at room temperature. The mixture was then extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with water (1 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (12:1) as the eluent to give 7-bromo-3a,7a-dihydro-2H-cyclohepta[b]benzofuran (140 mg) as a yellow oil. (ES, m / z): [M] = 224, 226.
[0265] 19.3 To a solution of 7-bromo-2H-spiro[1-benzofuran-3,1'-cyclopropane] (140 mg, 0.622 mmol, 1 equiv) in anhydrous THF (5 mL) was added dropwise n-butyllithium (0.37 mL, 0.933 mmol, 1.5 equiv, 2.5 M) under nitrogen at −78°C. The mixture was allowed to react for 1 hour, followed by the dropwise addition of a solution of 1-(1-(trityl)imidazol-4-yl)ethanone (263.05 mg, 0.746 mmol, 1.2 equiv) in THF (10 mL). The mixture was then stirred at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl(aq.) (20 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with water (1 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse-phase HPLC using the following conditions: C18 silica gel column; mobile phase: MeCN-water (10 mmol / L NH4HCO3), gradient from 30% to 70% over 10 minutes; detection: UV 220 nm. The product, 1-{2H-spiro-1-benzofuran-3,1'-cyclopropane]-7-yl}-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (100 mg), was obtained as a pale yellow oil. (ES, m / z): [M+1] = 499.
[0266] 19.4 Under nitrogen, 1-{2H-spiro-1-benzofuran-3,1'-cyclopropane]-7-yl}-1-[1-(triphenylmethyl)imidazol-4-yl]ethanol (90 mg, 0.186 mmol, 1 equiv) and triethylsilane (433.6 mg, 3.720 mmol, 20 equiv) were added to DCM (5 mL) and reacted for 1 minute. TFA (425.3 mg, 3.720 mmol, 20 equiv) was then added dropwise at room temperature, and the reaction was stirred for 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography using a C18 silica column, a mobile phase consisting of methanol-water (10 mmol / L NH4HCO3) with a gradient from 10% to 50% over 10 minutes, and a UV detector at 220 nm. 4-(1-{2H-spiro[1-benzofuran-3,1′-cyclopropane]-7-yl}vinyl)-1H-imidazole (25 mg) was obtained as a yellow oil. (ES, m / z): [M+1] = 239.
[0267] 19.5 Under nitrogen, to a methanol solution (5 mL) of 4-(1-{2H-spiro[1-benzofuran-3,1'-cyclopropane]-7-yl}vinyl)-1H-imidazole (25 mg, 0.105 mmol, 1 equiv) was added 10% Pd / C (10 mg), followed by stirring at room temperature under hydrogen for 30 minutes. The resulting mixture was filtered through Celite, washed with methanol (3 x 10 mL), and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography under the following conditions: column: C18 silica gel; mobile phase: MeCN-water (0.1% NH3.H2O + 10 mmol / L NH4HCO3), gradient from 10% to 50% over 10 minutes; detector: UV 220 nm. This afforded 4-[1-(2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)ethyl]-1H-imidazole (18.7 mg). (ES, m / z): [M+1] = 241. 1 H NMR (400 MHz, methanol-d4) δ 7.54 (s, 1H), 6.85–6.67 (m, 3H), 6.55 (dd, J = 7.3, 1.4 Hz, 1H), 4.47 (s, 2H), 4.31 (q, J = 7.2 Hz, 1H), 1.56 (d, J = 7.2 Hz, 3H), 1.01 (s, 4H).
[0268] Example 20 Preparation of 4-[1-(2-chloro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0269] 20.1 Under nitrogen atmosphere at room temperature, 4-bromo-7-chloro-2,3-dihydroindan-1-one (800 mg, 3.259 mmol, 1 equiv) and NaBH4 (246.55 mg, 6.518 mmol, 2 equiv) were added to a mixture of methanol (6 mL) and tetrahydrofuran (12 mL) and stirred for 2 hours. The mixture was quenched by the addition of saturated NH4Cl solution (aq) (50 mL) at 0°C. The resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with water (3 x 30 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography using PE / EA (7:1) as the eluent to afford 4-bromo-7-chloro-2,3-dihydro-1H-indan-1-ol (750 mg) as a colorless oil. (ES, m / z): [M] = 246, 248.
[0270] 20.2 To a solution of 4-bromo-7-chloro-2,3-dihydro-1H-inden-1-ol (1 g, 4.040 mmol, 1 equiv) in acetonitrile (20 mL) at room temperature under nitrogen was added p-toluenesulfonate (69.57 mg, 0.404 mmol, 0.1 equiv), and the reaction was stirred at 70°C for 3 h. The reaction solution was cooled to room temperature, diluted with water (15 mL), and then extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with water (3 x 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (8:1) to afford 4-bromo-7-chloro-3H-indene (300 mg) as a yellow solid. (ES, m / z): [M] = 228, 230.
[0271] 20.3 Under nitrogen at 0°C, diethylzinc solution (0.87 mL, 0.870 mmol, 5 equiv) and TFA (0.06 mL, 0.870 mmol, 5 equiv) were added to DCM (5 mL) and stirred for 20 minutes. Subsequently, diiodomethane (233.41 mg, 0.870 mmol, 5 equiv) was added dropwise at room temperature. A solution of 4-bromo-7-chloro-3H-indene (40 mg, 0.174 mmol, 1 equiv) in DCM (1 mL) was added. Stirring was continued at room temperature overnight. The mixture was quenched by addition of saturated NH4Cl(aq) solution (200 mL) at room temperature and extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with water (3 x 10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (12:1) as the eluent to afford 5-bromo-2-chloro-1H,1aH,6H,6aH-cyclopropyl[a]indene (32 mg) as a yellow solid. (ES, m / z): [M] = 242,244.
[0272] 20.4 To a solution of 5-bromo-2-chloro-1H,1aH,6H,6aH-cyclopropyl[a]indene (220 mg, 0.903 mmol, 1 equiv) in THF (5 mL) was added dropwise n-BuLi (0.54 mL, 1.355 mmol, 1.5 equiv, 2.5 M) under nitrogen at -78°C. A solution of 1-[1-(trityl)imidazol-4-yl]ethanone (382.06 mg, 1.084 mmol, 1.2 equiv) in THF (2 mL) was added dropwise under nitrogen at -78°C. The resulting mixture was stirred at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl(aq) (50 mL) at room temperature. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with water (3 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. A yellow solid product, 1-(2-chloro-1H,1aH,6H,6aH-cyclopropyl[a]indenyl)-1-[1-(trityl)imidazol-4-yl]ethanol (140 mg), was obtained. (ES, m / z): [M+1] = 517.
[0273] 20.5 At room temperature under nitrogen, 1-(2-chloro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl)-1-[(1-(triphenylmethyl)imidazol-4-yl)ethyl]ethanol (130 mg, 0.251 mmol, 1 equiv) and triethylsilane (292.34 mg, 2.510 mmol, 10 equiv) were added to DCM (3 mL), followed by the slow addition of TFA (0.19 mL, 2.510 mmol, 10 equiv). The reaction mixture was stirred at room temperature under nitrogen for 2 hours. The mixture was then concentrated under reduced pressure and purified by reverse phase chromatography using a C18 silica column, a mobile phase consisting of methanol-water (0.1% FA) with a gradient elution rate (10% to 50% over 10 minutes), and a UV detector at 254 nm. 4-(1-(2-chloro-1H,1aH,6H,6aH-cycloprop[a]inden-5-enylvinyl)-1H-imidazole) (35 mg) was obtained as a yellow solid. (ES, m / z): [M+1] = 257.
[0274] 20.6 To a methanol solution of 4-(1-(2-chloro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-ylvinyl)-1H-oxazole (30 mg, 0.117 mmol, 1 equiv) was added portionwise 10% Pd / C (10 mg) at room temperature under nitrogen. The reaction was stirred under hydrogen atmosphere at room temperature for 20 min. The resultant was filtered through celite, washed with methanol (3×10 mL), and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography under the following conditions: chromatographic column: C18 silica gel; mobile phase: MeCN-water (10 mmol / L NH 4 HCO 3 ), gradient from 10% to 50% in 10 min; detector: UV 254 nm. 4-[1-(2-chloro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole (15 mg) was obtained. (ES, m / z): [M+1] = 259. 1 H NMR(400MHz,Chloroform-d)δ7.44(d,J=1.1Hz,1H),7.05(dd,J=8.2,2.9Hz,1H),6. 83(dd,J=14.4,8.2Hz,1H),6.67(dt,J=7.5,1.1Hz,1H),4.01(q,J=7.1Hz,1H),3.17– 3.01(m,1H),3.01–2.85(m,1H),2.51(dtq,J=7.9,4.9,1.8Hz,1H),1.83(pd,J=7.0,4 .1Hz,1H),1.71–1.45(m,3H),1.11(dtd,J=15.6,8.0,4.5Hz,1H),0.14–0.01(m,1H).
[0275] Example 21 Preparation of 4-[1-(3-chloro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole
[0276] 21.1 To a solution of 4-bromo-6-chloro-2,3-dihydroindan-1-one (900 mg, 3.666 mmol, 1 equiv) in THF (10 mL) and MeOH (5 mL) was added NaBH4 (832.1 mg, 21.996 mmol, 6 equiv) under nitrogen at room temperature. The resulting mixture was stirred overnight under nitrogen at room temperature. Water (20 mL) was added to quench the mixture at room temperature. The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with water (1 x 20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (10:1) as the eluent to give 4-bromo-6-chloro-2,3-dihydro-1H-indan-1-ol (860 mg) as a colorless oil. (ES, m / z): [M+1] = 247, 249.
[0277] 21.2 To a solution of 4-bromo-6-chloro-2,3-dihydro-1H-inden-1-ol (680 mg, 2.747 mmol, 1 equiv) in acetonitrile was added p-toluenesulfonic acid (47.3 mg, 0.275 mmol, 0.1 equiv) under nitrogen at room temperature, and the reaction was stirred at 70°C under nitrogen for 2 h. The resulting residue was concentrated and purified by silica gel column chromatography using PE / EA (10:1) as the eluent to afford 4-bromo-6-chloro-3H-indenene (140 mg) as a colorless oil. (ES, m / z): [M+1] = 229, 231.
[0278] 21.3 ZnEt2 solution (3.05 mL, 3.050 mmol, 5 equiv) and TFA (347.78 mg, 3.050 mmol, 5 equiv) were added to DCM (10 mL) and allowed to react for 20 minutes. Diiodomethane (816.93 mg, 3.050 mmol, 5 equiv) was then added and allowed to react for 20 minutes. 4-Bromo-6-chloro-3H-indane (140 mg, 0.610 mmol, 1 equiv) was then added and stirred at room temperature overnight. The reaction was quenched by addition of saturated NH4Cl solution (20 mL). The reaction was then extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (1 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1:1) as the eluent to afford 5-bromo-3-chloro-1H,1aH,6H,6aH-cyclopropyl[a]indane (120 mg) as a colorless oil. (ES, m / z): [M+1] = 242,244.
[0279] 21.4 To a solution of 5-bromo-3-chloro-1H,1aH,6H,6aH-cyclopropylideneindene (100 mg, 0.411 mmol, 1 equiv) in 5 mL of THF was added anhydrous butyllithium (0.25 mL, 0.616 mmol, 1.5 equiv, 2.5 M) under nitrogen at -78°C and allowed to react for 60 minutes. A solution of 1-[1-(trityl)imidazol-4-yl]ethanone (173.66 mg, 0.493 mmol, 1.2 equiv) in THF (5 mL) was then added portionwise under the same conditions and stirred at room temperature overnight. The reaction was quenched by the addition of saturated NH4Cl(aq) (20 mL) at room temperature and extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with water (1 x 10 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using PE / EA (1:1) as the eluent to afford 1-{3-chloro-1H,1aH,6H,6aH-cyclopropylideneinden-5-yl}-1-[1-(trityl)imidazol-4-yl]ethanol (100 mg) as a yellow solid. (ES, m / z): [M+1] = 517.
[0280] 21.4 To a solution of 1-{3-chloro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl}-1-{1-(trityl)imidazol-4-yl}ethanol (100 mg, 0.193 mmol, 1 equiv) and triethylsilane (449.75 mg, 3.860 mmol, 20 equiv) in DCM (5 mL) was added trifluoromethanesulfonic acid (441.04 mg, 3.860 mmol, 20 equiv) in portions at room temperature under nitrogen, and the reaction was stirred for 2 hours. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase high-performance liquid chromatography using the following conditions: column, C18 silica gel; mobile phase, methanol-water (0.1% FA) gradient elution, from 10% to 50% over 10 minutes; detector, UV 254 nm. 4-(1-{3-chloro-1H,1aH,6H,6aH-cyclopropyl[a]inden-5-yl}vinyl)-1H-imidazole (20 mg) was obtained as a white solid. (ES, m / z): [M+1] = 257.
[0281] 21.5 To a solution of 4-(1-{3-chloro-1H,1aH,6H,6aH-cyclopropyl[a]indol-5-yl}vinyl)-1H-imidazole (20 mg, 0.078 mmol, 1 equiv) in methanol (5 mL) was added 10% Pd / C (10 mg) at room temperature under nitrogen, followed by a hydrogen atmosphere and stirring at room temperature for 30 minutes. The resulting mixture was filtered through celite, washed with MeOH (3 x 50 mL), and concentrated under reduced pressure. The residue was purified by HPLC under the following conditions (column: XBridge Shield RP18 OBD Column 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3 + 0.1% NH3.H2O); mobile phase B: ACN; flow rate: 60 mL / min; gradient: 30% B to 50% B; wavelength: 254 nm / 200 nm; RT1 (min): 11.83) to obtain 4-[1-(3-chloro-1,1a,6,6a-tetrahydrocyclopropyl[a]inden-5-yl)ethyl]-1H-imidazole (5.4 mg) as a white solid. (ES, m / z): [M+1] = 259. 1 H NMR(400MHz,Chloroform-d)δ7.22(s,1H),7.11(dd,J=3.6,1.9Hz,1H),6.84–6.61(m,2H),4.02(q,J=7.1Hz,1H),3.03–2 .72(m,2H),2.38–2.23(m,1H),1.93–1.74(m,1H),1.53(d,J=7.1Hz,3H),1.04(dtd,J=15.9,8.0,4.4Hz,1H),0.07(s,1H).
[0282] Example 22 Preparation of 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thien-3-yl)ethyl]-2-methyl-1H-imidazole
[0283] 22.1 2-Methyl-1H-imidazole-4-carbaldehyde (1 g, 9.081 mmol, 1 equiv) was added to DCM (50 mL), followed by Trt-Cl (3.04 g, 10.897 mmol, 1.2 equiv), and stirred overnight at room temperature under nitrogen. The reaction was quenched with water (10 mL). The resulting mixture was poured into 500 mL of saline solution and extracted with 3 x 500 mL of dichloromethane, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (4:1) as the eluent to afford 2-methyl-1-(triphenylmethyl)imidazole-4-carbaldehyde (2.3 g) as a white solid. (ES, m / z): [2M+1] = 705.
[0284] 22.2 Under nitrogen, trityl-2-methyl-1-imidazoline-4-carbaldehyde (2.3 g, 6.526 mmol, 1 equiv) was dissolved in THF (50 mL), and bromomethyl Grignard reagent (4.35 mL, 13.052 mmol, 2 equiv, 3 M) was added dropwise at 0°C. The reaction was stirred at room temperature for 4 hours. The reaction was quenched with saturated NH4Cl(aq) (10 mL) at room temperature. The reaction solution was added with brine (100 mL), extracted with ethyl acetate (3 x 100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3:1) to give 1-[2-methyl-1-(trityl)-imidazolin-4-yl]ethanol (2.3 g) as a white solid. (ES, m / z): [M+1] = 369.
[0285] 22.3 At room temperature, 1-[2-methyl-1-(triphenylmethyl)imidazol-4-yl]ethanol (800 mg, 2.171 mmol, 1 equiv), dioxane (20 mL), and manganese dioxide (377.49 mg, 4.342 mmol, 2 equiv) were added to a 40 mL sealed tube. The mixture was stirred overnight at 80°C under nitrogen. The mixture was cooled to room temperature, filtered through celite, and washed with DCM (3 x 10 mL). The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography eluting with PE / EA (1:1) to afford 1-[2-methyl-1-(triphenylmethyl)imidazol-4-yl]ethanone (520 mg, 65.36%) as a white solid. (ES, m / z): [2M+1] = 733.
[0286] 22.4 To a solution of 3-bromo-1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophene (200 mg, 0.881 mmol, 1.00 equiv) in THF (15 mL) was added n-BuLi (0.39 mL, 0.969 mmol, 1.1 equiv, 2.5 M) under nitrogen at −78° C. for 1 hour. A solution of 1-[2-methyl-1-(triphenylsilyl)imidazol-4-yl]ethanone (354.98 mg, 0.969 mmol, 1.1 equiv) in THF (5 mL) was then added dropwise. The mixture was stirred overnight at room temperature under nitrogen. The reaction was quenched by the addition of saturated NH4Cl(aq) (10 mL) at room temperature. The resulting mixture was added to brine (100 mL) and extracted with ethyl acetate (3×100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by reverse-phase chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN-water (10 mmol / L NH4HCO3), gradient from 50% to 80% over 10 minutes; detector, UV 220 nm. 1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)-1-(2-methyl-1-trityl-1H-imidazol-4-yl)ethan-1-ol (200 mg) was obtained as a white solid. (ES, m / z): [M+1] = 515.
[0287] 22.5 Under nitrogen, 1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)-1-(2-methyl-1-trityl-1H-imidazol-4-yl)ethan-1-ol (200 mg, 0.401 mmol, 1 equiv), THF (3 mL), triethylsilane (466.34 mg, 4.010 mmol, 10 equiv), and TFA (457.29 mg, 4.010 mmol, 10 equiv) were placed in a 6 mL sealed tube and stirred at 80°C overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN-water (10 mmol / L NH4HCO3), gradient from 10% to 50% over 10 minutes; detection, UV 220 nm. 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)vinyl]-2-methyl-1H-imidazole (80 mg) was obtained as a white solid. (ES, m / z): [M+1] = 255.
[0288] 22.6 To a 25 mL round-bottom flask was added 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thiophen-3-yl)vinyl]-2-methyl-1H-imidazole (60 mg, 0.236 mmol, 1 equiv), methanol (4 mL), and 10% Pd / C (30 mg), and stirred at room temperature. The mixture was then stirred at room temperature under hydrogen for 2 hours. The resulting mixture was filtered through celite, washed with methanol (3 x 5 mL), and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN-water (10 mmol / L NH4HCO3), gradient elution from 10% to 30% over 10 minutes; detection, UV 220 nm. 4-[1-(1a,6b-dihydro-1H-benzo[b]cyclopropyl[d]thien-3-yl)ethyl]-2-methyl-1H-imidazole (25 mg) was obtained. (ES, m / z): [M+1] = 257. 1 H NMR (400MHz, methanol-d4) δ7.18(dt,J=7.4,1.6Hz,1H),6.95(td,J=7.6,6.6Hz,1H),6.85(ddd,J =23.4,7.7,1.3Hz,1H),6.58(dd,J=24.7,1.0Hz,1H),3.83(q,J=7.1Hz,1H),3.04(dtd,J=8 .4,7.2,4.0Hz,1H),2.94(ddt,J=8.5,7.1,4.1Hz,1H),2.27(d,J=4.6Hz,3H),1.49(dd,J=7 .1,5.9Hz,3H),1.30(dddd,J=8.6,7.2,5.0,3.5Hz,1H),0.24(dtd,J=4.9,4.2,0.6Hz,1H).
[0289] Example 23 Preparation of 4-[1-(1,1a,2,7b-tetrahydrocyclopropyl[c]chroman-4-yl)ethyl]-1H-imidazole
[0290] 23.1 At room temperature under nitrogen, 4-[1-(2H-chroman-8-yl)ethyl]-1H-imidazole (200 mg, 0.884 mmol, 1 equiv) and trityl chloride (369.61 mg, 1.326 mmol, 1.5 equiv) were added to THF (4 mL), followed by the dropwise addition of TEA (178.88 mg, 1.768 mmol, 2 equiv). The resulting mixture was stirred at 50°C under nitrogen for 2 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford the crude product. Purification by silica gel column chromatography using PE / EA (6:1) afforded 4-[1-(2H-chroman-8-yl)ethyl]-1-trityl-1H-imidazole (237 mg) as a white oil. (ES, m / z): [M+1] = 469.
[0291] 23.2 To a solution of 4-[1-(2H-chroman-8-yl)ethyl]-1-trityl-1H-imidazole (150 mg, 0.320 mmol, 1 equiv) in 3 mL of THF was added Pd(OAc)2 (2.87 mg, 0.013 mmol, 0.04 equiv) at room temperature under nitrogen for 20 minutes. Subsequently, CH2N2 (16.01 mL, 3.200 mmol, 10 equiv) was added dropwise under nitrogen at -20°C, and the mixture was stirred at room temperature overnight. The resulting mixture was filtered, the filter cake washed with THF (3 x 10 mL), and the filtrate concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN-water (0.1% NH3·H2O), gradient from 10% to 50% over 10 minutes; detector, UV 220 nm. 4-[1-(1,1a,2,7b-tetrahydrocyclopropyl[c]chroman-4-yl)ethyl]-1-trityl-1H-imidazole (70 mg) was obtained. (ES, m / z): [M+1] = 483.
[0292] 23.3 4-[1-(1,1a,2,7b-tetrahydrocyclopropyl[c]chroman-4-yl)ethyl]-1-trityl-1H-imidazole (78 mg, 0.162 mol, 1 eq) and TFA (0.5 ml) were added to DCM (1.5 ml) at room temperature and stirred under hydrogen for 2 hours. The resulting mixture was concentrated under reduced pressure to obtain a crude product (70 mg), which was then purified by HPLC under the following conditions (column: XBridge Shield RP18 OBD Column 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L ammonium bicarbonate); mobile phase B: ACN; flow rate: 60 ml / min; gradient: 24% B to 44% B over 12 minutes; wavelength: 254 nm / 220 nm; RT1 (min): 10.85) to afford 4-[1-(1,1a,2,7b-tetrahydrocyclopropyl[c]chroman-4-yl)ethyl]-1H-imidazole (3.1 mg). (ES, m / z): [M+1] = 241.
[0293] 1 H NMR (400MHz, methanol-d4) δ7.52(d,J=1.3Hz,1H),7.05(ddt,J=6.3,3.9,2.0Hz,1H),6.80–6.68(m,3H),4.49–4.40(m,1H),4.33(ddd,J=10.5,7.8,1 .2Hz,1H),3.75(dd,J=10.4,1.6Hz,1H),2.01–1.93(m,1H),1.77(tddt,J=8.3,5.5,2.9,1.4Hz,1H),1.47(d,J=7.1Hz,3H),1.04–0.94(m,2H).
[0294] Biological test cases
[0295] Test Example 1: In vitro affinity
[0296] 1. Experimental Methods
[0297] 1.1 Preparation of buffer and test sample
[0298] Standard buffer (for preparation of α 1A , α 2A , α 2B , α 2C Receptor membrane: Weigh 146 mg of EDTA and add 50 mM Tris-HCl buffer to a total volume of 1000 mL, adjusting the pH to 7.7. The final concentration is 0.5 mM EDTA.
[0299] Test sample (compound): Calculate the theoretical sample weight according to the designed concentration and required volume. Generally 5.0×10-3 M is the initial preparation dose, which is dissolved in DMSO and then diluted with DMSO to 5.0×10 -4 M~5.0×10 - 9 M, dilute the diluted DMSO solution with Buffer to a working concentration of 5.0×10 -5 M~5.0×10 -11 M, the final concentration of DMSO in the working solution is 1% (the final concentration of DMSO in the reaction system is 0.2%). The test samples were stored at 4°C after preparation and discarded after the test.
[0300] 1.2 Preparation of receptor membrane
[0301] CHO-K1-α 1A ,CHO-K1-α 2A ,CHO-K1-α 2B ,CHO-K1-α 2C After removing cells from a -80°C freezer, thaw naturally and centrifuge at 2000g at 4°C for 10 min. Discard the supernatant and collect the pellet. Add buffer to the pellet and homogenize for 20-30 seconds. Centrifuge at 48,000g at 4°C for 25 minutes. Discard the supernatant. Add buffer again and homogenize for 20-30 seconds. Centrifuge at 48,000g at 4°C for 25 minutes. Discard the supernatant and collect the pellet. Store at -80°C.
[0302] 1.3 Receptor competition binding assay
[0303] 1.3.1 Radioactive binding test conditions
[0304] Table 1 Radioactive binding test conditions Note: Prazosin: Prazosin; RX821002: 2-Methoxyidazoxan monohydrochloride.
[0305] 1.3.2 Receptor Binding Assay Procedure
[0306] Step 1: Add 50 μL of solvent (1% DMSO) to the total binding tube (TB) and 50 μL of non-specific binding (final concentration 1.0×10 -5 M), and 50 μL of the test compound was added to each test compound tube (CB).
[0307] Step 2: Add 100 μL of buffer to each reaction tube.
[0308] Step 3: Use the prepared membrane buffer to make a membrane suspension of corresponding concentration for later use.
[0309] Step 4: Add 50 μL of the corresponding radioligand to each reaction tube.
[0310] Step 5: Add 50 μL of membrane solution to each reaction tube.
[0311] Step 6: Incubate each reaction tube according to the incubation conditions. After the reaction is complete, the bound ligand is filtered by vacuum rapid filtration. UniFilter GF / C plates are saturated with 0.5% PEI solution 1 hour in advance, washed thoroughly with ice-cold Tris-HCl buffer, filtered, and dried in a constant temperature drying oven for 30 minutes. Remove the filter plate and add MICROSCINT PS scintillation fluid (40 μL / well).
[0312] Step 7: Place the scintillation cup into the liquid scintillation counter for counting.
[0313] 1.4 Data Analysis
[0314] According to the effect values of the compound samples at different concentration test points, GraphPad Prism software was used to fit the compound sample-receptor action curve and calculate the Ki value.
[0315] 1.5 Experimental Results
[0316] Compounds 1, 2, 4 and α 2A The receptor affinity of compounds 3 and 5 is comparable to that of dexmedetomidine. 2A The receptor affinity of compounds 1, 4, and 5 is better than that of dexmedetomidine; 1A / 2A The α of compounds 2 and 3 is comparable to that of dexmedetomidine. 1A / 2A It is superior to dexmedetomidine. See Table 2 for details.
[0317] Test Example 2: In vitro function
[0318] 2. Experimental Methods
[0319] 2.1 Objective: To detect adrenergic receptors (α 1A , α 2A , α 2B , α 2C ) signaling pathway, and calculate the EC of the compound. 50 The agonist effect of the dexmedetomidine series compounds on adrenaline receptors was evaluated by RT-PCR.
[0320] 2.2 Experimental Materials
[0321] Cell line: 293-α 1A Stable cell line (Shanghai Shujing Biotechnology Co., Ltd.)
[0322] 293-α2A Stable cell line (Shanghai Shujing Biotechnology Co., Ltd.)
[0323] CHO-α 2B / Gα15 stably transfected cell line (Nanjing GenScript Biotechnology Co., Ltd.)
[0324] CHO-α 2C / Gα15 stably transfected cell line (Nanjing GenScript Biotechnology Co., Ltd.)
[0325] Cell culture conditions:
[0326] 293-α 1A (DMEM, 10% FBS, 0.6μg / mL puromycin)
[0327] 293-α 2A (DMEM, 10% FBS, 0.6μg / mL puromycin)
[0328] CHO-α 2B / Gα15 (F12, 10% FBS, 200 μg / mL Zeocin, 100 μg / mL Hygromycin B)
[0329] CHO-α 2C / Gα15 (F12, 10% FBS, 400 μg / mL G418, 400 μg / mL Hygromycin B)
[0330] Reagents and consumables:
[0331] F12 (meilunbio, MA0229)
[0332] DMEM (Gibco, 8121703)
[0333] FBS (BOVOGEN, SFBS)
[0334] Zeocin (Invitrogen, R25001)
[0335] Hygromycin B (invitrogen, 10687010)
[0336] Puromycin (Solarbio, 119L042)
[0337] PBS (meilunbio, MA0015)
[0338] Pancreatin (Gibco, 25200-072)
[0339] 96-cell plate (cisbio, 66PL96025)
[0340] cAMP-Gi kit (cisbio, 03E)
[0341] IP-ONE Kit (cisbio, 16E)
[0342] CO2 incubator (Thermo, 311)
[0343] Centrifuge (Shanghai Anting, TGL-16C)
[0344] Cell counter (Countstar, IC1000)
[0345] Microplate reader (PerkinElmer, EnVision)
[0346] 2.3 Experimental steps
[0347] 2.3.1 Agonist screening mode cAMP assay (epinephrine α 2A receptors)
[0348] (1) Prepare the reaction buffer (1x Stimulation buffer) required for the experiment: dilute the 5x Stimulation buffer in the Cisbio cAMP-Gi kit with ddH2O in a ratio of 1:4 and set aside.
[0349] (2) Compound preparation: Dilute the compound to a 5 mM stock solution with DMSO, then dilute it 3.16-fold to form 10 gradients, and then dilute the prepared compound to the corresponding concentration (2.5x) with stimulation buffer for later use.
[0350] (3) Cell preparation: Trypsin digestion of 293-α on culture dishes 2A Cells were washed with culture medium and collected into a 5 mL centrifuge tube. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant. Add 3 mL of PBS and mix thoroughly by gently pipetting. Centrifuge again at 1000 rpm for 5 minutes and discard the supernatant. Resuspend the cells in 1x Stimulation buffer and count using a Countstar cell counter. Adjust the cell density to 4 x 10 5 / mL, for future use.
[0351] (4) Cell addition: Add the cell suspension to the experimental plate, 5 μL / well (i.e., approximately 2000 cells / well).
[0352] (5) Compound addition: Add the compound diluted with Stimulation buffer to the above experimental plate, 4 μL / well.
[0353] (6) Reaction incubation: After slow shaking, incubate the experimental plate at 37°C for 20 minutes.
[0354] (7) Addition of agonist Forskolin: Add 10x adenylate cyclase agonist (final concentration 1 μM Forskolin) solution, 1 μL / well.
[0355] (8) Reaction incubation: After slow shaking, incubate the experimental plate at 37°C for 45 minutes.
[0356] (9) Add detection reagents: Dilute cAMP-cryptate and Anti-cAMP-d2 at a 1:20 ratio using the Lysis & Detection Buffer in the Cisbio cAMP-Gi Assay Kit. Add 5 μL of each diluted cAMP-cryptate and Anti-cAMP-d2 to the assay plate. After shaking, incubate the plate at room temperature for 60 minutes.
[0357] (10) Experimental reading: Read the plate on Envision, detect the readings of the 665nm and 615nm channels, and calculate the ratio of 665nm / 615nm readings.
[0358] 2.3.2 Agonist Screening Mode IP-One Assay (epinephrine α 1A , α 2B , α 2C receptors)
[0359] (1) Prepare the reaction buffer (1x Stimulation buffer) required for the experiment: dilute the 5x Stimulation buffer in the Cisbio IP-One kit with ddH2O in a ratio of 1:4 and set aside.
[0360] (2) Compound preparation: Dilute the compound to a 5 mM stock solution with DMSO, then dilute it 3.16-fold to form 10 gradients, and then dilute the prepared compound to the corresponding concentration (2x) with stimulation buffer for later use.
[0361] (3) Cell preparation: Trypsin digestion of 293-α on culture dishes 1A ,CHO-α 2B ,CHO-α 2CCells were washed with culture medium and collected into a 5 mL centrifuge tube. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant. Add 3 mL of PBS and mix thoroughly by gently pipetting. Centrifuge again at 1000 rpm for 5 minutes and discard the supernatant. Resuspend the cells in 1x Stimulation buffer and count using a Countstar cell counter to adjust the cell density to 1.7 x 10 6 / mL, for future use.
[0362] (4) Cell addition: Add the cell suspension to the experimental plate, 7 μL / well (i.e., approximately 12,000 cells / well).
[0363] (5) Compound addition: Add the compound diluted with Stimulation buffer to the above experimental plate, 7 μL / well.
[0364] (6) Reaction incubation: After slow shaking, the experimental plate was incubated at 37°C for 60 minutes.
[0365] (7) Add detection reagents: Dilute IP1-cryptate and Anti-IP1-d2 at a 1:12 ratio using the Lysis & Detection Buffer in the Cisbio IP-One Detection Kit. Add 3 μL of each diluted cAMP-cryptate and Anti-cAMP-d2 to the assay plate. After shaking, incubate the plate at room temperature for 60 minutes.
[0366] (8) Experimental reading: Read the plate on Envision, detect the readings of the 665nm and 615nm channels, and calculate the ratio of 665nm / 615nm readings.
[0367] 2.4 Data Analysis
[0368] According to the agonist effect values of the compound samples at different concentrations, the data were analyzed and statistically analyzed using the graphing software GraphPad Prism5 (log(agonist) vs. normalized response--Variable slope, n≥2), and the EC was calculated. 50 .
[0369] 2.5 Experimental Results
[0370] Compounds 1, 4, 11, and 15 of the present invention are effective against α 2A The agonist activity of compounds 2, 3, and 5 on α 2A The agonist activity of the receptor is better than that of dexmedetomidine; the α 1A / 2A It is superior to dexmedetomidine. See Table 2 for details.
[0371] Table 2 In vitro affinity and functional data “ a "It means it is better than the right beauty," b "It means it is equivalent to Youmei.
[0372] Test Example 3: Hypnotic Effect
[0373] Experimental methods
[0374] The ED of the compounds of the present invention in rats with loss of righting reflex (LORR) was determined by sequential method. 50 (50% effective dose): Male SD rats, weighing 200-300 g, were given an initial dose of each compound dissolved in physiological saline via the tail vein at a constant rate of 10 seconds (one rat was given each dose). If the rat's righting reflex disappeared after the initial dose, the next rat was given a lower dose (0.8 times the initial dose). If the rat's righting reflex did not disappear after the initial dose, the next rat was given a higher dose (1.25 times the initial dose), and so on. The results were entered into the AOT425 StatPgm software until the software could produce the ED value. 50 , the experiment ends. 50 Evaluation of the hypnotic efficacy of the compounds of the present invention, ED 50 The smaller the value, the stronger the drug effect.
[0375] Comparison of onset time and duration of effect: Male SD rats weighing 200-300 g were given a dose of 2 times the ED after each compound was dissolved in physiological saline and injected into the tail vein at a constant speed of 10 seconds. There were 10 rats in each group. 50 (ED 50 : the dose that causes loss of righting reflex in 50% of rats), and record the onset time and maintenance time.
[0376] The onset time refers to the time after the injection when the rat is placed in the supine position. The rat's front paw cannot turn over to the prone position on its own and the time is maintained for ≥10 seconds, which is considered to be the standard of the rat's righting reflex disappearance. It is used as an indicator of the compound's effectiveness. The maintenance time refers to the duration of the rat's righting reflex disappearance. The drug effect is considered to have subsided after the rat's righting reflex recovers on its own.
[0377] 3.2 Experimental Results
[0378] The results are shown in Table 3:
[0379] Table 3 Hypnotic efficacy data Note: Compared with dexmedetomidine hydrochloride, * p<0.05, ** p<0.01.
[0380] Experimental results showed that the hypnotic onset time of the compounds of the present invention was comparable to or slightly longer than that of dexmedetomidine, but all compounds were able to induce sleep in rats within 5 minutes, demonstrating a definite and reversible hypnotic effect. Compound 2 had an onset time and duration comparable to those of dexmedetomidine. Compounds 3, 5, 11, and 15 had durations significantly shorter than those of dexmedetomidine, demonstrating clinical value and significance, and expanding the application scenarios of the compounds.
[0381] Test Example 4: Blood Pressure and Heart Rate Fluctuations After Administration
[0382] Experimental methods
[0383] Male SD rats, weighing 250-300 g, 4 rats per group, were placed under general anesthesia with isoflurane inhalation, cannulated through the femoral artery, and monitored for blood pressure and heart rate using a Powerlab data acquisition and analysis system. 30 minutes after the baseline values stabilized, the baseline mean arterial pressure (MAP0) and baseline heart rate (HR0) were measured. The rats were injected with physiological saline solutions of each compound via the tail vein (the dosage of each compound was the same as in Test Example 3, with a rapid intravenous injection of 10 seconds), and blood pressure and heart rate were continuously recorded for 90 minutes. The maximum mean arterial pressure (MAP0) within 90 minutes was calculated. max ) and MAP0 + , mean arterial pressure nadir (MAP min ) and MAP0 - , Heart rate minimum (HR min ) and HR0 - Calculate the maximum rate of increase in mean arterial pressure = MAP + / MAP0*100%, maximum reduction rate of mean arterial pressure = MAP - / MAP0*100%, maximum heart rate reduction rate = HR - / HR0*100%. See Table 4 for details.
[0384] 4.2 Experimental results
[0385] The experimental results showed that rats did not experience significant fluctuations in blood pressure or heart rate after injection of normal saline (fluctuations less than 10%). After dexmedetomidine administration, the MAP of the animals showed a bidirectional change, initially increasing and then decreasing, with MAP and HR decreasing continuously for 90 minutes. Compound 2 showed comparable MAP and HR changes to dexmedetomidine. Compounds 3 and 5 did not show a significant decrease in MAP greater than 10%, and HR recovered more rapidly than dexmedetomidine. Compounds 11 and 15 showed significantly lower MAP increases and no significant decreases than dexmedetomidine hydrochloride, while their maximum HR decreases were significantly lower than dexmedetomidine hydrochloride and recovered more rapidly.
[0386] Table 4 Fluctuations of blood pressure and heart rate after administration Note: “ / ” indicates no relevant impact or not applicable.
Claims
1. A compound as shown in formula I or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, in, X is selected from C(R2) p ,O,S,NR2; p is selected from 1 and 2; n is an integer selected from 1-3, preferably 1; Each R1 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl; Each R2 is independently selected from H, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, C1-C8 alkylthio, halogen, hydroxyl, nitro, cyano, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl, and the substituents are independently selected from halogen, C1-C8 alkoxy, hydroxyl, nitro, cyano; R3 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C3-C8 cycloalkyl, C1-C8 haloalkylthio, C3-C8 halocycloalkyl; Ring A is selected from 5-8 membered heterocyclyl, C4-C8 cycloalkyl; R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl optionally substituted by one or more Rb, or a 4-8 membered heterocyclyl optionally substituted by one or more Rb; the one or more Rb are independently selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxyl, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxyl; v is an integer selected from 1-5, preferably an integer selected from 1-3, and more preferably 1 or 2; Each R6 is independently selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, nitro, cyano, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C2-C8 haloalkenyl, C2-C8 haloalkynyl, optionally substituted C3-C8 cycloalkyl, C1-C8 haloalkylthio; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy.
2. The compound of formula I as claimed in claim 1 or its pharmaceutically acceptable salt, stereoisomer, or tautomer, characterized in that: One or more of the following conditions are met: (1) Ring A is selected from a 5-8 membered heterocyclic group containing 1-3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and a C4-C8 cycloalkyl group; preferably selected from a 5-6 membered heterocyclic group containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and a C4-C6 cycloalkyl group; further preferably selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, dihydropyrrolyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl, dihydropyridinyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutyl alkenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl; further preferably selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, dihydropyrrolyl, pyrrolidinyl; further preferably selected from tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, cyclopentyl, cyclopentenyl, pyrrolidinyl, tetrahydrothiopyranyl, dihydrothiopyranyl, cyclohexyl, cyclohexenyl; (2) R4, R5 and the carbon atom to which they are attached together form a C3-C8 cycloalkyl group optionally substituted by one or more Rb, or a 4-8 membered heterocyclic group optionally substituted by one or more Rb containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen; the C3-C8 cycloalkyl group is preferably a cyclopropyl, cyclopropenyl, cyclobutenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl or cyclohexenyl, more preferably a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and even more preferably a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The 4-8 membered heterocyclic group containing 1-2 heteroatoms independently selected from oxygen, sulfur and nitrogen is preferably oxetanyl, thietanyl, azetidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydropyrrolyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl, dihydropyridinyl, and further preferably oxetanyl, thietanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl, dihydropyridinyl, and further preferably oxetanyl, thietanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiopyranyl, dihydrothiopyranyl; (3) Rb is selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, nitro, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted The substituents are independently selected from halogen, C1-C8 alkyl, hydroxyl, preferably halogen, and more preferably F.
3. The compound of formula I or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof as claimed in claim 1 or 2, characterized in that: One or more of the following conditions are met: (1) X is CHR2; (2) R1 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, C1-C8 alkyl, hydroxy, halogen; (3) R2 is selected from H, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, C1-C8 alkylthio, halogen, hydroxy, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, optionally substituted C1-C8 alkyl; the substituents are independently selected from halogen and hydroxy; (4) R3 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C3-C6 cycloalkyl, C1-C8 haloalkylthio, C3-C6 fluorocycloalkyl; preferably H, halogen, C1-C8 alkyl; (5) R6 is selected from H, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C8 haloalkylthio, preferably H, halogen, C1-C8 alkyl, more preferably H, C1-C8 alkyl; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy, preferably halogen, more preferably F.
4. The compound of formula I according to claim 1 or its pharmaceutically acceptable salt, stereoisomer, or tautomer, characterized in that: One or more of the following conditions are met: (1) Rb is selected from halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, nitro, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C5 haloalkylthio, preferably H, halogen, C1-C5 alkyl, more preferably H, halogen, C1-C3 alkyl; the substituents are independently selected from halogen, C1-C5 alkyl, hydroxy, preferably halogen, more preferably F; (2) R1 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, C1-C5 alkyl, hydroxy, halogen, More preferably, H, C1-C3 alkyl, hydroxyl, halogen; (3) R2 is selected from H, optionally substituted C1-C5 alkyl, optionally substituted C1-C5 alkoxy, C1-C5 alkylthio, halogen, hydroxy, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, optionally substituted C1-C5 alkyl, more preferably H, optionally substituted C1-C3 alkyl; the substituents are independently selected from halogen and hydroxy; (4) R3 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C3-C6 cycloalkyl, C1-C5 haloalkylthio, C3-C6 fluorocycloalkyl, preferably H, halogen, C1-C5 alkyl, more preferably H, halogen, C1-C3 alkyl; (5) R6 is selected from H, halogen, C1-C5 alkyl, C1-C5 alkoxy, hydroxy, C1-C5 hydroxyalkyl, C1-C5 hydroxyalkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, C1-C5 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C5 haloalkylthio, preferably H, halogen, C1-C5 alkyl, more preferably H, C1-C3 alkyl; the substituents are independently selected from halogen, C1-C5 alkyl, hydroxy, preferably halogen, more preferably F.
5. The compound of formula I or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof according to any one of claims 1 to 3, characterized in that: R4, R5 and the carbon atoms to which they are respectively attached together form a C3-C8 cycloalkyl or 4-8 membered heterocyclic group optionally substituted by one or more Rb, wherein the C3-C8 cycloalkyl or 4-8 membered heterocyclic group is fused to ring A; preferably, any of the following fused rings is formed: More preferably Further preferably More preferably m is an integer selected from 0-4, preferably 0, 1, 2; Rb is selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, nitro, C1-C8 hydroxyalkyl, C1-C8 hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C8 haloalkylthio, preferably halogen, C1-C8 alkyl; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxy, preferably halogen, and more preferably F.
6. A compound of formula I according to any one of claims 1 to 3 or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, characterized in that: R4, R5 and the carbon atom to which they are commonly connected together form a C3-C8 cycloalkyl or 4-8 membered heterocyclic group optionally substituted by one or more Rb, wherein the C3-C8 cycloalkyl or 4-8 membered heterocyclic group is spiro-bonded to ring A, preferably forming any of the following spirocyclic groups: More preferably More preferably m is an integer selected from 0-4, preferably 0, 1, 2; Rb is selected from halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxy, nitro, C1-C8 hydroxyalkyl, C1-C8 Hydroxyalkoxy, C1-C8 haloalkyl, C1-C8 haloalkoxy, C1-C8 alkylthio, optionally substituted C3-C6 cycloalkyl, C1-C8 haloalkylthio, preferably H, halogen, C1-C8 alkyl; the substituents are independently selected from halogen, C1-C8 alkyl, hydroxyl, preferably halogen, and more preferably F.
7. The compound of formula I or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof according to any one of claims 1 to 6, characterized in that: Ring A is selected from Preferably More preferably More preferably 8. The compound of formula I according to claim 1 or its pharmaceutically acceptable salt, stereoisomer, or tautomer, characterized in that: The compound of formula I is shown in formula II: Wherein, Q is selected from C, O, N, S, preferably C, O, S; y is selected from 1 and 2; v is selected from 1, 2, 3, 4; n, X, R1, R3, R4, R5 and R6 are as defined in claim 1.
9. The compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, characterized in that: Selected from the following compounds:
10. A pharmaceutical composition, characterized in that Containing the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof, and a pharmaceutically acceptable carrier.
11. Use of the compound according to any one of claims 1 to 9 or its pharmaceutically acceptable salt, stereoisomer, tautomer, or the pharmaceutical composition according to claim 10 in the preparation of drugs related to α2 adrenergic receptor agonists, preferably in the preparation of drugs that produce sedation, and / or analgesia, and / or anesthetic effects, and / or anti-anxiety, and / or inhibition of sympathetic nerve activity, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals, and further preferably in the preparation of drugs that produce sedation, and / or analgesia, and / or anesthetic effects, and / or treatment of insomnia, and / or treatment of mental disorders in humans or animals.
12. A compound of formula IA, formula I-A', formula IB, IC, I-C' or ID or a salt thereof, In formula IA, n, v, R1, R3, R4, R5, and R6 are as defined in the corresponding groups in claims 1 to 9; R7 is selected from H, C1-C5 alkyl, preferably H, methyl; R9 is selected from an amino protecting group; preferably a trityl group; In formula I-A', n, R1, R3, R4, R5, and R6 are as defined in the corresponding groups in claims 1 to 9; R7 is selected from H, C1-C5 alkyl, preferably H, methyl; In formula IB, X, n, v, R1, R3, R4, R5, and R6 are as defined in the corresponding groups in claims 1 to 9; R9 is selected from an amino protecting group; preferably a trityl group; In formula IC, n, v, R1, R3, R4, R5, and R6 are as defined in the corresponding groups in claims 1 to 9; R 10 Selected from C1-C6 alkyl, preferably methyl, ethyl; R9 is selected from an amino protecting group; preferably a trityl group; In formula I-C', n, v, R1, R3, R4, R5, and R6 are as described above; R9 is selected from an amino protecting group; preferably a trityl group; In formula ID, n, v, R1, R3, R4, R5, and R6 are as defined in the corresponding groups in claims 1 to 9; R9 is selected from amino protecting groups; preferably trityl.
13. A method for preparing the compound according to any one of claims 1 to 9, characterized in that: The method comprises the following steps: a brominated aromatic cyclized compound is subjected to lithium-halogen exchange under the action of butyl lithium, and then a nucleophilic attack is made on an acyl imidazole derivative to obtain an intermediate IC; or a brominated aromatic cyclized compound is subjected to lithium-halogen exchange under the action of butyl lithium, and then a nucleophilic attack is made on a formyl imidazole derivative to obtain an intermediate I-C'. n, v, R1, R4, R5, R6 as defined in the corresponding groups of claims 1-9; R 10 Selected from C1-C6 alkyl, preferably methyl, ethyl; R9 is selected from amino protecting groups; preferably trityl.
Citation Information
Patent Citations
4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
CN101052638A
Use of 4-imidazole derivatives for CNS disorders
CN101374832A
Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(ALPHA) inhibitors
CN113874350A
Hypoxia inducible factor-2 (alpha) inhibitors and their use in treatment of disease
CN115485262A
Quinolynylmethylimidizoles as therapeutic agents
US20100076020A1
Cited By
Imidazole modulators for the treatment of pain and hypertension
WO2026085512A1
